Salt crystal form of plinabulin

Abstract

The present invention provides a salt crystal form of plinabulin. Specifically, the present invention provides a salt crystal form of a compound as represented by formula I. The salt crystal form of the present invention has excellent solubility, hygroscopicity and pharmacokinetic properties.

Description

FIELD OF THE INVENTION The present invention relates to the field of pharmaceutical chemistry, specifically, relates to a salt crystal form of plinabulin, the preparation methods therefor and the use thereof. BACKGROUND OF THE INVENTION Plinabulin, ((3Z,6Z)-3-[(5-tert-butyl-1H-imidazol-4-yl)methylene]-6-(benzylidene)-2,5-piperazinedione), is a synthetic analogue of phenylahistin, a diketopiperazine isolated from marine and terrestrial Aspergillus species, whose structure is shown below. () M ™ 'AA-''11 O / V" Structurally, plinabulin differs from colchicine and combretastatin-like analogues thereof (e.g., combretastatin phosphate), and binds at or near the colchicine-binding site on tubulin monomers. Previous studies have demonstrated that, compared with colchicine, plinabulin induces depolymerization of tubulin in vascular endothelial cells and monolayer permeability at low concentrations, and triggers apoptosis in Jurkat leukemia cells. Studies of plinabulin as a single agent in patients with advanced malignant tumors (lung cancer, prostate cancer and colon cancer) have exhibited favorable pharmacokinetic, pharmacodynamic and safety profiles. Nevertheless, there remains a need to provide a salt crystal form of plinabulin with appropriate physicochemical properties to improve its solubility in solvents. SUMMARY OF THE INVENTION The object of the present invention is to provide a salt crystal form of plinabulin which possesses excellent solubility and hygroscopicity, features a simple preparation process, and facilitates the industrial production of plinabulin. The first aspect of the present invention provides a salt crystal form of a compound of Formula I: wherein, the salt crystal form is selected from the group consisting of oxalate salt crystal form, maleate salt crystal form, fumarate salt crystal form, succinate salt crystal form, D-tartrate salt crystal form, L-tartrate salt crystal form, D-malate salt crystal form, L-malate salt crystal form, L-glutamate salt crystal form, citrate salt crystal form, benzoate salt crystal form, salicylate salt crystal form, methanesulfonate salt crystal form, ethanesulfonate salt crystal form, benzenesulfonate salt crystal form, p-toluenesulfonate salt crystal form, acetate salt crystal form, trifluoroacetate salt crystal form, propionate salt crystal form, hydrochloride salt crystal form, hydrobromide salt crystal form, sulfate salt crystal form, phosphate salt crystal form, and nitrate salt crystal form. In another preferred embodiment, the oxalate salt crystal form is oxalate salt crystal Form 1, wherein the X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at three or more (e.g., 4, or 5) 20 values selected from the group consisting of 10.3±0.2, 12.5±0.2, 23.9±0.2, 25.4±0.2, and 29.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at five or more (e.g., 6, 7, 8, or 9) 20 values selected from the group consisting of 5.2±0.2, 10.3±0.2, 12.5±0.2, 16.1±0.2, 18.3±0.2, 19.4±0.2, 22.7±0.2, 23.1±0.2, 23.9±0.2, 25.4±0.2, 25.8±0.2, and 29.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at ten or more (e.g., 12, 14, 15,16, or 18) 20 values selected from the group consisting of 5.2±0.2, 8.4±0.2, 10.3±0.2, 12.5±0.2, 14.2±0.2, 14.6±0.2, 15.3±0.2, 16.1±0.2, 17.2±0.2, 18.3±0.2, 19.1±0.2, 19.4±0.2, 22.7±0.2, 23.1±0.2, 23.5±0.2, 23.9±0.2, 25.4±0.2, 25.8±0.2, and 29.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at the following 20 values: 3.9±0.2, 5.2±0.2, 7.7±0.2, 8.4±0.2, 10.3±0.2, 12.5±0.2, 14.2±0.2, 14.6±0.2, 15.3±0.2, 16.1±0.2, 17.2±0.2, 18.3±0.2, 18.8±0.2, 19.1±0.2, 19.4±0.2, 21.5±0.2, 22.7±0.2, 23.1±0.2, 23.5±0.2, 23.9±0.2, 25.0±0.2, 25.4±0.2, 25.8±0.2, 26.5±0.2, 28.0±0.2, 29.0±0.2, 29.9±0.2, and 37.0±0.2. In another preferred embodiment, the crystal Form 1 has an X-ray powder diffraction pattern substantially as shown in Figure 2. In another preferred embodiment, the crystal Form 1 has an NMR spectrum substantially as shown in Figure 1. In another preferred embodiment, the crystal Form 1 has a thermogravimetric curve substantially as shown in Figure 3. In another preferred embodiment, the crystal Form 1 undergoes gradual weight loss upon initiation of heating, with a termination temperature ranging from 210 to -240 °C (e.g., 230 °C); the second stage weight lose has an onset temperature of 260 to -300 °C (e.g., 290 °C), until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to oxalic acid in the crystal Form 1 is 0.8-1.5:0.8-1.5, for example 1:1, 1:1.2, 1:1.4, or 1:1.5. In another preferred embodiment, the maleate salt crystal form is maleate salt crystal Form 2, wherein the X-ray powder diffraction pattern of the crystal Form 2 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 6.7±0.2, 16.5±0.2, 22.3±0.2, and 25.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 2 includes diffraction peaks at five or more (e.g., 6, 7, 8, or 9) 20 values selected from the group consisting of 6.7±0.2, 16.5±0.2, 18.5±0.2, 19.4±0.2, 19.8±0.2, 20.1±0.2, and 29.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 2 includes diffraction peaks at ten or more (e.g., twelve, fourteen, fifteen, sixteen, or seventeen) 20 values selected from the group consisting of 6.7±0.2, 12.5±0.2, 16.0±0.2, 16.5±0.2, 18.5±0.2, 19.4±0.2, 19.8±0.2, 20.1±0.2, 22.3±0.2, 22.7±0.2, 23.5±0.2, 24.8±0.2, 25.4±0.2, 28.5±0.2, 29.4±0.2, and 30.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 2 includes diffraction peaks at the following 20 values: 6.7±0.2, 12.5±0.2, 13.4±0.2, 14.6±0.2, 15.0±0.2, 15.6±0.2, 16.0±0.2, 16.5±0.2, 17.8±0.2, 18.5±0.2, 19.4±0.2, 19.8±0.2, 20.1±0.2, 21.6±0.2, 22.3±0.2, 22.7±0.2, 23.5±0.2, 24.8±0.2, 25.4±0.2, 26.0±0.2, 26.8±0.2, 28.5±0.2, 29.4±0.2, and 30.6±0.2. In another preferred embodiment, the crystal Form 2 has an X-ray powder diffraction pattern substantially as shown in Figure 5. In another preferred embodiment, the crystal Form 2 has an NMR spectrum substantially as shown in Figure 4. In another preferred embodiment, the crystal Form 2 has a thermogravimetric curve substantially as shown in Figure 6. In another preferred embodiment, the thermogravimetric test of the crystal Form 2 comprises two weight-loss processes, the first-stage weight loss has an onset temperature from 160 to -220 °C (e.g., 200 °C), and a termination temperature from 230 to -260 °C (e.g., 250 °C); the second-stage weight loss has an onset temperature from 270 to -300 °C (e.g., 280 °C), and continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to maleic acid in the crystal Form 2 is 0.8-1.2:0.8-1.2, for example 1:1. In another preferred embodiment, the fumarate salt crystal form is fumarate salt crystal Form 3, wherein the X-ray powder diffraction pattern of the crystal Form 3 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 6.6±0.2, 16.4±0.2, 20.0±0.2, 22.2±0.2, and 25.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 3 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 6.6±0.2, 12.4±0.2, 15.9±0.2, 16.4±0.2, 18.5±0.2, 19.7±0.2, 20.0±0.2, 22.2±0.2, 23.4±0.2, 24.8±0.2, 25.3±0.2, 28.5±0.2, and 29.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 3 includes diffraction peaks at ten or more (e.g., 12, 14, 15 or 16) 20 values selected from the group consisting of 6.6±0.2, 12.4±0.2, 15.9±0.2, 16.4±0.2, 18.5±0.2, 19.4±0.2, 19.7±0.2, 20.0±0.2, 22.2±0.2, 22.6±0.2, 23.4±0.2, 24.8±0.2, 25.3±0.2, 28.5±0.2, 29.4±0.2, and 30.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 3 includes diffraction peaks at the following 20 values: 6.6±0.2, 9.8±0.2, 11.2±0.2, 12.4±0.2, 13.3±0.2, 14.6±0.2, 14.9±0.2, 15.6±0.2, 15.9±0.2, 16.4±0.2, 17.8±0.2, 18.5±0.2, 19.4±0.2, 19.7±0.2, 20.0±0.2, 22.2±0.2, 22.6±0.2, 23.4±0.2, 24.8±0.2, 25.3±0.2, 25.9±0.2, 26.8±0.2, 28.5±0.2, 29.4±0.2, 30.5±0.2, and 33.3±0.2. In another preferred embodiment, the crystal Form 3 has an X-ray powder diffraction pattern substantially as shown in Figure 8. In another preferred embodiment, the crystal Form 3 has an NMR spectrum substantially as shown in Figure 7. In another preferred embodiment, the crystal Form 3 has a thermogravimetric curve substantially as shown in Figure 9. In another preferred embodiment, the thermogravimetric test of the crystal Form 3 comprises two weight-loss processes, the first-stage weight loss has an an onset temperature from 110 to 150 °C (e.g., 130 °C), and a termination temperature from 240 to 270 °C (e.g., 260 °C); the second-stage weight loss has an the onset temperature from 270 to -300 °C (e.g., 280 °C), and continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to fumaric acid in the crystal Form 3 is 0.8-1.2:0.8-1.2, for example 1:1. In another preferred embodiment, the succinate salt crystal form is succinate salt crystal Form 4, wherein the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 20.1±0.2, 26.2±0.2, and 31.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 20.1±0.2, 23.9±0.2, 24.3±0.2, 26.2±0.2, 26.6±0.2, 29.4±0.2, and 31.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at ten or more (e.g., 11, 12, 13, 14 or 15) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 16.3±0.2, 17.7±0.2, 19.2±0.2, 20.1±0.2, 22.9±0.2, 23.9±0.2, 24.3±0.2, 24.6±0.2, 25.4±0.2, 26.2±0.2, 26.6±0.2, 29.4±0.2, and 31.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at the following 20 values: 8.2±0.2, 13.1±0.2, 14.8±0.2, 16.1±0.2, 16.3±0.2, 17.7±0.2, 19.2±0.2, 20.1±0.2, 22.4±0.2, 22.9±0.2, 23.9±0.2, 24.3±0.2, 24.6±0.2, 25.4±0.2, 26.2±0.2, 26.6±0.2, 29.4±0.2, and 31.6±0.2. In another preferred embodiment, the crystal Form 4 has an X-ray powder diffraction pattern substantially as shown in Figure 11. In another preferred embodiment, the crystal Form 4 has an NMR spectrum substantially as shown in Figure 10. In another preferred embodiment, the molar ratio of the compound of Formula I to succinic acid in the crystal Form 4 is 0.8-1.2:0.8-1.2, for example 1:1. In another preferred embodiment, the D-tartrate salt crystal form is D-tartrate salt crystal Form 5, wherein the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 7.0±0.2, 18.5±0.2, 22.2±0.2, 25.07±0.2, and 26.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 7.0±0.2, 9.1±0.2, 12.9±0.2, 17.6±0.2,  18.1±0.2, 18.5±0.2, 20.1±0.2, 22.2±0.2, 25.07±0.2, and 26.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at ten or more (e.g., 11, 12, 13, 14 or 15) 20 values selected from the group consisting of 7.0±0.2, 9.1±0.2, 11.8±0.2, 12.3±0.2, 12.9±0.2, 17.3±0.2, 17.6±0.2, 18.1±0.2, 18.5±0.2, 20.1±0.2, 22.2±0.2, 25.07±0.2, 26.0±0.2, and 27.9±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at the following 20 values: 7.0±0.2, 9.1±0.2, 11.8±0.2, 12.3±0.2, 12.9±0.2,  17.3±0.2,  17.6±0.2,  18.1±0.2,  18.5±0.2, 20.1±0.2, 20.7±0.2, 21.07±0.2, 22.2±0.2, 25.07±0.2, 26.0±0.2, 27.9±0.2, and 28.7±0.2. In another preferred embodiment, the crystal Form 5 has an X-ray powder diffraction pattern substantially as shown in Figure 13. In another preferred embodiment, the crystal Form 5 has an NMR spectrum substantially as shown in Figure 12. In another preferred embodiment, the molar ratio of the compound of Formula I to D-tartaric acid in the crystal Form 5 is 0.8-1.2:0.8-1.2, for example 1:1. In another preferred embodiment, the L-tartrate salt crystal form is L-tartrate salt crystal Form 6, wherein the X-ray powder diffraction pattern of the crystal Form 6 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 23.8±0.2, 24.2±0.2, and 26.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 6 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 16.1±0.2, 19.2±0.2, 22.9±0.2, 23.8±0.2, 24.2±0.2, 25.4±0.2, 26.6±0.2, and 29.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 6 includes diffraction peaks at ten or more (e.g., 12, 14, 16, 18 or 20) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 14.8±0.2, 15.5±0.2, 16.1±0.2, 16.3±0.2, 17.6±0.2, 19.2±0.2, 19.4±0.2, 22.4±0.2, 22.9±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.4±0.2, 26.6±0.2, 27.5±0.2, 29.3±0.2, 31.8±0.2, and 33.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 6 includes diffraction peaks at the following 20 values: 8.2±0.2, 8.6±0.2, 9.2±0.2, 11.2±0.2, 13.1±0.2, 13.9±0.2, 14.1±0.2, 14.8±0.2, 15.5±0.2, 16.1±0.2, 16.3±0.2, 17.6±0.2, 18.5±0.2, 19.2±0.2, 19.4±0.2, 19.8±0.2, 20.9±0.2, 21.2±0.2, 22.4±0.2, 22.9±0.2, 23.4±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.4±0.2, 25.8±0.2, 26.6±0.2, 27.2±0.2, 27.5±0.2, 27.9±0.2, 28.3±0.2, 28.9±0.2, 29.3±0.2, 29.9±0.2, 31.3±0.2, 31.8±0.2, 32.4±0.2, 33.0±0.2, 35.7±0.2, and 38.6±0.2. In another preferred embodiment, the crystal Form 6 has an X-ray powder diffraction pattern substantially as shown in Figure 15. In another preferred embodiment, the crystal Form 6 has an NMR spectrum substantially as shown in Figure 14. In another preferred embodiment, the molar ratio of the compound of Formula I to L-tartaric acid in the crystal Form 6 is 0.8-1.2:0.8-1.2, for example 1:1. In another preferred embodiment, the D-malate salt crystal form is D-malate salt crystal Form 7, wherein the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 8.1±0.2, 23.8±0.2, 24.2±0.2, and 24.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at five or more (e.g., 6, 7, 8, or 9) 20 values selected from the group consisting of 8.1±0.2, 13.0±0.2, 16.2±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 26.5±0.2, and 29.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 17) 20 values selected from the group consisting of 8.1±0.2, 13.0±0.2, 16.0±0.2, 16.2±0.2, 17.6±0.2, 19.1±0.2, 19.7±0.2, 20.8±0.2, 22.4±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 25.3±0.2, 26.5±0.2, and 29.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at the following 20 values: 8.1±0.2, 9.2±0.2, 11.1±0.2, 13.0±0.2, 13.9±0.2, 14.1±0.2, 14.8±0.2, 15.4±0.2, 16.0±0.2, 16.2±0.2, 17.6±0.2, 18.4±0.2, 19.1±0.2, 19.7±0.2, 20.8±0.2, 21.2±0.2, 22.4±0.2, 22.8±0.2, 23.4±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 25.3±0.2, 25.7±0.2, 26.5±0.2, 27.1±0.2, 27.4±0.2, 27.9±0.2, 28.3±0.2, 28.9±0.2, 29.3±0.2, 30.6±0.2, 31.2±0.2, 31.7±0.2, 32.4±0.2, 32.9±0.2, 35.7±0.2, 38.5±0.2, and 38.8±0.2. In another preferred embodiment, the crystal Form 7 has an X-ray powder diffraction pattern substantially as shown in Figure 17. In another preferred embodiment, the crystal Form 7 has an NMR spectrum substantially as shown in Figure 16. In another preferred embodiment, the molar ratio of the compound of Formula I to D-malic acid in the crystal Form 7 is 0.8-1.2:0.8-1.2, for example 1:1, 1:1.1, or 1:1.2. In another preferred embodiment, the L-malate salt crystal form is L-malate salt crystal Form 8, wherein the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 10.2±0.2, 20.0±0.2, 20.6±0.2, 33.7±0.2, and 35.7±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9 or 10) 20 values selected from the group consisting of 10.2±0.2, 20.0±0.2, 20.6±0.2, 21.5±0.2, 22.1±0.2, 24.3±0.2, 26.2±0.2, 28.9±0.2, 33.7±0.2, and 35.7±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at ten or more (e.g., 12, 13, 14, 15 or 16) 20 values selected from the group consisting of 10.2±0.2, 20.0±0.2, 20.6±0.2, 21.5±0.2, 22.1±0.2, 23.8±0.2, 24.3±0.2, 25.7±0.2, 26.2±0.2, 28.9±0.2, 30.1±0.2, 31.1±0.2, 33.1±0.2, 33.7±0.2, 35.7±0.2, and 38.0±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at the following 20 values: 10.2±0.2, 13.8±0.2, 20.0±0.2, 20.6±0.2, 21.5±0.2, 22.1±0.2, 23.2±0.2, 23.8±0.2, 24.3±0.2, 25.7±0.2, 26.2±0.2, 27.7±0.2, 28.9±0.2, 30.1±0.2, 31.1±0.2, 33.1±0.2, 33.7±0.2, 35.7±0.2, 38.0±0.2, and 38.7±0.2. In another preferred embodiment, the crystal Form 8 has an X-ray powder diffraction pattern substantially as shown in Figure 19. In another preferred embodiment, the crystal Form 8 has an NMR spectrum substantially as shown in Figure 18. In another preferred embodiment, the molar ratio of the compound of Formula I to L-malic acid in the crystal Form 8 is 0.8-1.2:0.8-1.2, for example 1:1, or 1:1.1. In another preferred embodiment, the L-glutamate salt crystal form is L-glutamate salt crystal Form 9, wherein the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 19.8±0.2, 22.5±0.2, and 23.1±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, 10 or 11) 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.7±0.2, 17.2±0.2, 17.5±0.2, 19.8±0.2, 20.6±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, and 27.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.7±0.2, 15.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.8±0.2, 20.6±0.2, 22.1±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.9±0.2, 26.4±0.2, 27.5±0.2, 28.6±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at the following 20 values: 7.3±0.2, 11.2±0.2, 14.7±0.2, 15.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.8±0.2, 20.6±0.2, 22.1±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.9±0.2, 26.4±0.2, 27.5±0.2, 28.6±0.2, 29.2±0.2, 30.4±0.2, and 39.2±0.2. In another preferred embodiment, the crystal Form 9 has an X-ray powder diffraction pattern substantially as shown in Figure 21. In another preferred embodiment, the crystal Form 9 has an NMR spectrum substantially as shown in Figure 20. In another preferred embodiment, the molar ratio of the compound of Formula I to L-glutamic acid in the crystal Form 9 is 0.8-1.2:0.8-1.2, for example 1:1, or 1:1.1. In another preferred embodiment, the citrate salt crystal form is citrate salt crystal Form 10, wherein the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 7.3±0.2, 17.1±0.2, 19.7±0.2, 23.1±0.2, and 23.8±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 7.3±0.2, 8.1±0.2, 17.1±0.2, 17.4±0.2, 19.7±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 27.5±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at ten or more (e.g., 12, 14, 16, 18 or 20) 20 values selected from the group consisting of 7.3±0.2, 8.1±0.2, 11.2±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.2±0.2, 24.8±0.2, 26.6±0.2, 27.5±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at the following 20 values: 3.5±0.2, 7.3±0.2, 8.1±0.2, 11.2±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 16.0±0.2, 16.3±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 24.8±0.2, 25.3±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 27.9±0.2, 28.6±0.2, 29.2±0.2, 30.4±0.2, 32.0±0.2, 33.0±0.2, 33.9±0.2, 34.1±0.2, 35.3±0.2, 38.6±0.2, and 39.1±0.2. In another preferred embodiment, the crystal Form 10 has an X-ray powder diffraction pattern substantially as shown in Figure 23. In another preferred embodiment, the crystal Form 10 has an NMR spectrum substantially as shown in Figure 22. In another preferred embodiment, the molar ratio of the compound of Formula I to citric acid in the crystal Form 10 is 0.8-1.2:0.8-1.2, for example 1:0.9, 1:1, or 1:1.1. In another preferred embodiment, the benzoate salt crystal form is benzoate salt crystal Form 11, wherein the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 23.1±0.2, and 23.8±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at five or more (e.g., 6, 7, 8 or 9) 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 17.5±0.2, 19.7±0.2, 20.6±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, and 27.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at ten or more (e.g., 12, 14, 16, 18 or 19) 20 values selected from the group consisting of 7.3±0.2, 11.0±0.2, 11.2±0.2, 14.6±0.2, 15.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.7±0.2, 20.6±0.2, 21.4±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 27.5±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at the following 20 values: 7.3±0.2, 8.1±0.2, 11.0±0.2, 11.2±0.2, 12.3±0.2, 14.6±0.2, 15.4±0.2, 16.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.7±0.2, 20.6±0.2, 21.4±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 28.6±0.2, 29.2±0.2, 30.4±0.2, 31.0±0.2, 33.0±0.2, 33.9±0.2, 35.3±0.2, and 39.2±0.2. In another preferred embodiment, the crystal Form 11 has an X-ray powder diffraction pattern substantially as shown in Figure 25. In another preferred embodiment, the crystal Form 11 has an NMR spectrum substantially as shown in Figure 24. In another preferred embodiment, the molar ratio of the compound of Formula I to benzoic acid in the crystal Form 11 is 0.8-1.2:0.8-1.2, for example 1:1, 1:1.1, or 1:1.2. In another preferred embodiment, the salicylate salt crystal form is salicylate salt crystal Form 12, wherein the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 7.3±0.2, 17.1±0.2, 19.7±0.2, 23.1±0.2, and 27.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9 or 10) 20 values selected from the group consisting of 7.3±0.2, 17.1±0.2, 17.4±0.2, 19.7±0.2, 20.6±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 27.5±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 12.3±0.2, 14.6±0.2, 15.4±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.8±0.2, 25.7±0.2, 27.5±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at the following 20 values: 6.2±0.2, 7.3±0.2, 11.2±0.2, 12.3±0.2, 14.6±0.2, 15.4±0.2, 16.4±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 25.4±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 28.5±0.2, 29.2±0.2, 30.4±0.2, 31.0±0.2, 31.5±0.2, 32.0±0.2, 33.0±0.2, 34.0±0.2, 35.3±0.2, 39.1±0.2. In another preferred embodiment, the crystal Form 12 has an X-ray powder diffraction pattern substantially as shown in Figure 27. In another preferred embodiment, the crystal Form 12 has an NMR spectrum substantially as shown in Figure 26. In another preferred embodiment, the molar ratio of the compound of Formula I to salicylic acid in the crystal Form 12 is 0.8-1.2:0.8-1.2, for example 1:0.9, 1:1, 1:1.1, or 1:1.2. In another preferred embodiment, the methanesulfonate salt crystal form is methanesulfonate salt crystal Form 13, wherein the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 12.1±0.2, 15.6±0.2, 19.8±0.2, 23.0±0.2, and 26.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at six or more (e.g., 7, 8, 10 or 12) 20 values selected from the group consisting of 9.9±0.2, 12.1±0.2, 15.6±0.2, 16.5±0.2, 18.0±0.2, 18.9±0.2, 19.8±0.2, 20.5±0.2, 21.0±0.2, 23.0±0.2, 23.9±0.2, 24.9±0.2, and 26.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 9.9±0.2, 12.1±0.2, 15.6±0.2, 16.5±0.2, 18.0±0.2, 18.9±0.2, 19.8±0.2, 20.5±0.2, 21.0±0.2, 21.9±0.2, 23.0±0.2, 23.5±0.2, 23.9±0.2, 24.9±0.2, 26.3±0.2, 26.7±0.2, 27.9±0.2, 28.3±0.2, 28.8±0.2, and 31.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at the following 20 values: 9.9±0.2, 12.1±0.2, 14.2±0.2, 14.6±0.2, 15.6±0.2, 16.5±0.2, 18.0±0.2, 18.9±0.2, 19.8±0.2, 20.5±0.2, 21.0±0.2, 21.9±0.2, 23.0±0.2, 23.5±0.2, 23.9±0.2, 24.4±0.2, 24.9±0.2, 26.3±0.2, 26.7±0.2, 27.4±0.2, 27.9±0.2, 28.3±0.2, 28.8±0.2, 29.4±0.2, 29.9±0.2, 30.4±0.2, 31.2±0.2, 31.6±0.2, 33.5±0.2, 34.2±0.2, 35.1±0.2, 37.9±0.2, and 39.2±0.2. In another preferred embodiment, the crystal Form 13 has an X-ray powder diffraction pattern substantially as shown in Figure 29. In another preferred embodiment, the crystal Form 13 has an NMR spectrum substantially as shown in Figure 28. In another preferred embodiment, the crystal Form 13 has a thermogravimetric curve substantially as shown in Figure 30. In another preferred embodiment, the thermogravimetric test of the crystal Form 13 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 150 to- 180 °C (e.g., 170 °C); the second-stage weight loss has an onset temperature from 250 to -280 °C (e.g., 270 °C), and continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to methanesulfonic acid in the crystal Form 13 is 1:0.8-20, for example 1:1, 1:1.5, 1:2, 1:5, 1:10, or 1:15. In another preferred embodiment, the ethanesulfonate salt crystal form is ethanesulfonate salt crystal Form 14, wherein the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 5.5±0.2, 9.89±0.2, 20.9±0.2, 23.4±0.2, and 25.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at six or more (e.g., 8, 10, 12 or 13) 20 values selected from the group consisting of 5.5±0.2, 8.7±0.2, 9.89±0.2, 11.7±0.2, 15.1±0.2, 16.6±0.2, 17.3±0.2, 18.4±0.2, 20.9±0.2, 21.9±0.2, 23.4±0.2, 25.4±0.2, and 27.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 5.5±0.2, 8.7±0.2, 9.89±0.2, 11.7±0.2, 13.6±0.2, 14.2±0.2, 15.1±0.2, 16.0±0.2, 16.6±0.2, 17.3±0.2, 17.9±0.2, 18.4±0.2, 19.8±0.2, 20.9±0.2, 21.9±0.2, 23.4±0.2, 24.4±0.2, 25.4±0.2, and 27.6±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at the following 20 values: 4.2±0.2, 5.5±0.2, 7.6±0.2, 8.7±0.2, 9.89±0.2, 11.7±0.2, 13.6±0.2, 14.2±0.2, 15.1±0.2, 16.0±0.2, 16.6±0.2, 17.3±0.2, 17.9±0.2, 18.4±0.2, 19.8±0.2, 20.9±0.2, 21.9±0.2, 23.4±0.2, 24.4±0.2, 25.4±0.2, 27.6±0.2, 28.7±0.2, 30.7±0.2, and 37.2±0.2. In another preferred embodiment, the crystal Form 14 has an X-ray powder diffraction pattern substantially as shown in Figure 32. In another preferred embodiment, the crystal Form 14 has an NMR spectrum substantially as shown in Figure 31. In another preferred embodiment, the crystal Form 14 has a thermogravimetric curve substantially as shown in Figure 33. In another preferred embodiment, the thermogravimetric test of the crystal Form 14 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 100 to 140 °C (e.g., 120 °C); the second-stage weight loss has an onset temperature from 230 to -270 °C (e.g., 250 °C), and continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to ethanesulfonic acid in the crystal Form 14 is 1:0.8-20, for example 1:1, 1:1.5, 1:2, 1:5, 1:10, or 1:15. In another preferred embodiment, the benzenesulfonate salt crystal form is benzenesulfonate salt crystal Form 15, wherein the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 5.7±0.2, 16.2±0.2, 17.4±0.2, 18.4±0.2, and 22.8±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at six or more (e.g., 8, 9, 10 or 12) 20 values selected from the group consisting of 5.7±0.2, 13.7±0.2, 14.9±0.2, 16.2±0.2, 16.6±0.2, 17.4±0.2, 18.4±0.2, 22.4±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, and 25.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 5.7±0.2, 6.8±0.2, 8.6±0.2, 10.9±0.2, 12.5±0.2, 13.7±0.2, 14.9±0.2, 16.2±0.2, 16.6±0.2, 17.4±0.2, 18.4±0.2, 19.5±0.2, 19.9±0.2, 22.4±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, and 25.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at the following 20 values: 5.7±0.2, 6.8±0.2, 8.6±0.2, 9.0±0.2, 9.3±0.2, 10.0±0.2, 10.9±0.2, 11.5±0.2, 12.5±0.2, 13.7±0.2, 14.9±0.2, 16.2±0.2, 16.6±0.2, 17.4±0.2, 18.4±0.2, 19.5±0.2, 19.9±0.2, 20.6±0.2, 22.4±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, 25.2±0.2, 26.3±0.2,  27.6±0.2, 28.8±0.2, 29.7±0.2, 30.4±0.2, 36.3±0.2, and 36.7±0.2. In another preferred embodiment, the crystal Form 15 has an X-ray powder diffraction pattern substantially as shown in Figure 35. In another preferred embodiment, the crystal Form 15 has an NMR spectrum substantially as shown in Figure 34. In another preferred embodiment, the crystal Form 15 has a thermogravimetric curve substantially as shown in Figure 36. In another preferred embodiment, the thermogravimetric test of the crystal Form 15 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 260 to 300 °C (e.g., 280 °C); the second-stage weight loss has an onset temperature from 260 to 300 °C (e.g., 280 °C), and continues until complete decomposition in the end. In another preferred embodiment, the molar ratio of the compound of Formula I to benzenesulfonic acid in the crystal Form 15 is 1:0.8-5, for example 1:0.9, 1:1, 1:1.2, 1:1.5, or 1:2. In another preferred embodiment, the p-toluenesulfonate salt crystal form is p-toluenesulfonate salt crystal Form 16, wherein the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 6.6±0.2, 15.1±0.2, 16.2±0.2, 21.5±0.2, and 24.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 6.6±0.2, 8.5±0.2, 8.8±0.2,  14.3±0.2,  15.1±0.2,  16.2±0.2, 21.5±0.2, 23.6±0.2, 24.5±0.2, and 27.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 17) 20 values selected from the group consisting of 6.6±0.2, 8.5±0.2, 8.8±0.2, 14.3±0.2, 15.1±0.2, 16.2±0.2, 17.0±0.2, 17.7±0.2, 18.5±0.2, 18.8±0.2, 20.0±0.2, 21.5±0.2, 23.6±0.2, 24.5±0.2, 27.4±0.2, 28.4±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at the following 20 values: 6.3±0.2, 6.6±0.2, 8.5±0.2, 8.8±0.2, 12.7±0.2, 14.3±0.2, 15.1±0.2, 16.2±0.2, 17.0±0.2, 17.7±0.2, 18.5±0.2, 18.8±0.2, 20.0±0.2, 20.4±0.2, 21.5±0.2, 22.4±0.2, 23.6±0.2, 24.0±0.2, 24.5±0.2, 26.2±0.2, 27.4±0.2, 28.4±0.2, 29.2±0.2, and 31.5±0.2. In another preferred embodiment, the crystal Form 16 has an X-ray powder diffraction pattern substantially as shown in Figure 38. In another preferred embodiment, the crystal Form 16 has an NMR spectrum substantially as shown in Figure 37. In another preferred embodiment, the crystal Form 16 has a thermogravimetric curve substantially as shown in Figure 39. In another preferred embodiment, in the thermogravimetric test of the crystal Form 16, gradual weight loss occurs from the onset of heating until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to p-toluenesulfonic acid in the crystal Form 16 is 1:0.8-2, for example 1:0.9, 1:1, 1:15, 1:1.2, or 1:1.5. In another preferred embodiment, the acetate salt crystal form is acetate salt crystal Form 17, wherein the X-ray powder diffraction pattern of the crystal Form 17 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 23.8±0.2, 24.2±0.2, and 26.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 17 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 16.0±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.3±0.2, 26.5±0.2, and 29.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 17 includes diffraction peaks at ten or more (e.g., 12, 13, 14, 15 or 16) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 14.8±0.2, 16.0±0.2, 17.6±0.2, 19.1±0.2, 19.8±0.2, 20.8±0.2, 22.4±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.3±0.2, 26.5±0.2, and 29.3±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 17 includes diffraction peaks at the following 20 values: 8.2±0.2, 9.2±0.2, 11.2±0.2, 13.1±0.2, 13.9±0.2, 14.1±0.2, 14.8±0.2, 15.5±0.2, 16.0±0.2, 16.3±0.2, 17.6±0.2, 18.4±0.2, 19.1±0.2, 19.8±0.2, 20.8±0.2, 21.2±0.2, 22.4±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.3±0.2, 25.7±0.2, 26.5±0.2,  27.1±0.2, 27.4±0.2, 27.9±0.2, 28.3±0.2; 28.9±0.2, 29.3±0.2, 30.6±0.2, 31.2±0.2, 31.7±0.2, 32.4±0.2, 33.0±0.2, 34.6±0.2, 35.7±0.2, 37.2±0.2, and 38.5±0.2. In another preferred embodiment, the crystal Form 17 has an X-ray powder diffraction pattern substantially as shown in Figure 41. In another preferred embodiment, the crystal Form 17 has an NMR spectrum substantially as shown in Figure 40. In another preferred embodiment, the molar ratio of the compound of Formula I to acetic acid in the crystal Form 17 is 1:0.8-2, for example 1:0.9, 1:1, 1:15, 1:1.2, 1:1.5 or 1:1.8. In another preferred embodiment, the trifluoroacetate salt crystal form is trifluoroacetate salt crystal Form 18, wherein the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 9.3±0.2, 17.0±0.2, 18.6±0.2, and 25.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at six or more (e.g., 7, 8, or 9) 20 values selected from the group consisting of 9.3±0.2, 10.5±0.2, 17.0±0.2, 18.6±0.2, 20.5±0.2, 21.1±0.2, 23.9±0.2, 25.4±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 6.7±0.2, 9.3±0.2, 10.5±0.2, 13.6±0.2, 15.5±0.2, 17.0±0.2, 18.6±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2, 22.3±0.2, 23.5±0.2, 23.9±0.2, 24.7±0.2, 25.4±0.2, 26.1±0.2, 26.9±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at the following 20 values: 6.7±0.2, 9.3±0.2, 10.5±0.2, 13.6±0.2, 14.8±0.2, 15.5±0.2, 17.0±0.2, 17.6±0.2, 18.1±0.2, 18.6±0.2, 19.6±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2, 22.3±0.2, 22.9±0.2, 23.5±0.2, 23.9±0.2, 24.4±0.2, 24.7±0.2, 25.4±0.2, 26.1±0.2, 26.9±0.2, 27.4±0.2, 28.0±0.2, 28.7±0.2, 29.2±0.2, 29.9±0.2, 31.1±0.2, 31.7±0.2, 32.8±0.2, 34.5±0.2, 35.9±0.2, 37.0±0.2, and 37.8±0.2. In another preferred embodiment, the crystal Form 18 has an X-ray powder diffraction pattern substantially as shown in Figure 43. In another preferred embodiment, the crystal Form 18 has an NMR spectrum substantially as shown in Figure 42. In another preferred embodiment, the crystal Form 18 has a thermogravimetric curve substantially as shown in Figure 44. In another preferred embodiment, the thermogravimetric test of the crystal Form 18 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 230 to 280 °C (e.g., 250 °C); the second-stage weight loss has ane onset temperature from 230 to 280 °C (e.g., 250 °C), and continues until complete decomposition in the end. In another preferred embodiment, the molar ratio of the compound of Formula I to trifluoroacetic acid in the crystal Form 18 is 1:0.8-20, for example 1:1, 1:1.5, 1:2, 1:5, 1:10, or 1:15. In another preferred embodiment, the propionate salt crystal form is propionate salt crystal Form 19, wherein the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 17.4±0.2, 22.5±0.2, and 23.1±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.6±0.2, 17.2±0.2, 17.4±0.2, 19.7±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, and 27.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at ten or more (e.g., 12, 13, 14, 15, or 16) 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.6±0.2, 15.4±0.2, 17.2±0.2, 17.4±0.2, 18.0±0.2, 19.7±0.2, 20.6±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.8±0.2, 26.6±0.2, 27.5±0.2, 28.5±0.2, and 29.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at the following 20 values: 7.3±0.2, 11.2±0.2, 14.6±0.2, 15.4±0.2, 16.4±0.2, 17.2±0.2, 17.4±0.2, 18.0±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 28.5±0.2, 29.2±0.2, 30.4±0.2, 31.6±0.2, 32.0±0.2, 33.0±0.2, 34.1±0.2, 35.3±0.2, 36.9±0.2, and 39.1±0.2. In another preferred embodiment, the crystal Form 19 has an X-ray powder diffraction pattern substantially as shown in Figure 46. In another preferred embodiment, the crystal Form 19 has an NMR spectrum substantially as shown in Figure 45. In another preferred embodiment, the molar ratio of the compound of Formula I to propionic acid in the crystal Form 19 is 1:0.8-30, for example 1:1, 1:1.5, 1:2, 1:5, 1:10, 1:15, 1:20, 1:25, or 1:28. In another preferred embodiment, the hydrochloride salt crystal form is hydrochloride salt crystal Form 20, wherein the X-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 12.2±0.2, 13.7±0.2, 21.0±0.2, 21.6±0.2, and 22.8±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 4.6±0.2, 9.1±0.2, 12.2±0.2, 13.7±0.2, 21.0±0.2, 21.6±0.2, 22.8±0.2, 23.3±0.2, 24.1±0.2, and 28.8±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 4.6±0.2, 9.1±0.2, 12.2±0.2, 13.7±0.2, 14.5±0.2, 17.7±0.2, 19.0±0.2, 19.7±0.2, 21.0±0.2, 21.6±0.2, 22.8±0.2, 23.3±0.2, 24.1±0.2, 24.6±0.2, 26.2±0.2, 27.5±0.2, 28.8±0.2, and 32.2±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at the following 20 values: 4.6±0.2, 9.1±0.2, 12.2±0.2, 13.7±0.2, 14.5±0.2, 15.1±0.2, 17.7±0.2, 18.2±0.2, 19.0±0.2, 19.7±0.2, 21.0±0.2, 21.6±0.2, 22.8±0.2, 23.3±0.2, 24.1±0.2, 24.6±0.2, 24.9±0.2, 26.2±0.2, 26.6±0.2, 27.2±0.2, 27.5±0.2, 28.5±0.2, 28.8±0.2, 29.7±0.2, 30.2±0.2, 30.6±0.2, 31.7±0.2, 32.2±0.2, 33.0±0.2, 35.3±0.2, 36.0±0.2, and 38.8±0.2. In another preferred embodiment, the crystal Form 20 has an X-ray powder diffraction pattern substantially as shown in Figure 48. In another preferred embodiment, the crystal Form 20 has an NMR spectrum substantially as shown in Figure 47. In another preferred embodiment, the crystal Form 20 has a thermogravimetric curve substantially as shown in Figure 49. In another preferred embodiment, the thermogravimetric test of the crystal Form 20 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 130 to 180 °C (e.g., 150 °C); the second-stage weight loss has an onset temperature from 250 to 300 °C (e.g., 280 °C), and continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to hydrochloric acid in the crystal Form 20 is 1:0.8-20, for example 1:1, 1:2, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, or 1:35. In another preferred embodiment, the hydrobromide salt crystal form is hydrobromide salt crystal Form 21, wherein the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at three or more (e.g., 4, 5 or 6) 20 values selected from the group consisting of 11.2±0.2, 17.7±0.2, 19.7±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, and 24.7±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at six or more (e.g., 8, 10, 12 or 13) 20 values selected from the group consisting of 11.2±0.2, 11.4±0.2, 14.8±0.2, 17.7±0.2, 19.7±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, 24.7±0.2, 26.1±0.2, 27.6±0.2, 28.3±0.2, and 29.9±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at ten or more (e.g., 12, 15, 18, 20 or 24) 20 values selected from the group consisting of 9.0±0.2, 11.2±0.2, 11.4±0.2, 12.1±0.2, 14.8±0.2, 15.9±0.2, 16.1±0.2, 17.7±0.2, 19.4±0.2, 19.7±0.2, 20.2±0.2, 20.9±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, 24.7±0.2, 26.1±0.2, 26.3±0.2, 27.6±0.2, 28.3±0.2, 29.9±0.2, 31.5±0.2, and 33.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at the following 20 values: 9.0±0.2, 11.2±0.2, 11.4±0.2, 12.1±0.2, 12.8±0.2, 13.5±0.2, 14.8±0.2, 15.9±0.2, 16.1±0.2, 17.2±0.2, 17.7±0.2, 18.9±0.2, 19.4±0.2, 19.7±0.2, 20.2±0.2, 20.9±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, 24.7±0.2, 25.1±0.2, 25.5±0.2, 26.1±0.2, 26.3±0.2, 26.8±0.2, 27.3±0.2, 27.6±0.2, 28.3±0.2, 28.8±0.2, 29.7±0.2, 29.9±0.2, 30.5±0.2, 31.5±0.2, 32.3±0.2, 32.6±0.2, 32.9±0.2, 33.4±0.2, 34.6±0.2, 36.6±0.2, 37.0±0.2, and 38.6±0.2. In another preferred embodiment, the crystal Form 21 has an X-ray powder diffraction pattern substantially as shown in Figure 51. In another preferred embodiment, the crystal Form 21 has an NMR spectrum substantially as shown in Figure 50. In another preferred embodiment, the crystal Form 21 has a thermogravimetric curve substantially as shown in Figure 52. In another preferred embodiment, the thermogravimetric test of the crystal Form 21 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 280 to 320 °C (e.g., 300 °C); the second-stage weight loss has an onset temperature from 300 to 350°C (e.g., 310 °C), and continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to hydrobromic acid in the crystal Form 21 is 1:0.8-5, for example 1:0.9, 1:1, 1:1.5, 1:2, 1:3, or 1:5. In another preferred embodiment, the sulfate salt crystal form is sulfate salt crystal Form 22, wherein the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 4.3±0.2, 12.4±0.2, 20.5±0.2, and 23.5±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 4.3±0.2, 8.4±0.2, 12.4±0.2, 14.4±0.2, 16.8±0.2, 20.5±0.2, 23.5±0.2, 23.8±0.2, 25.8±0.2, and 33.8±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at ten or more (e.g., 12, 13, 15, 18 or 20) 20 values selected from the group consisting of 4.3±0.2, 8.4±0.2, 12.4±0.2, 14.4±0.2, 16.8±0.2, 17.2±0.2, 18.3±0.2, 19.3±0.2, 20.5±0.2, 23.0±0.2, 23.5±0.2, 23.8±0.2, 24.1±0.2, 24.7±0.2, 24.9±0.2, 25.8±0.2, 26.4±0.2, 33.8±0.2, 34.6±0.2, and 35.9±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at the following 20 values: 4.3±0.2, 8.4±0.2, 10.5±0.2, 12.4±0.2, 14.4±0.2, 14.7±0.2, 15.3±0.2, 16.4±0.2, 16.8±0.2, 17.2±0.2, 18.3±0.2, 19.1±0.2, 19.3±0.2, 20.5±0.2, 21.0±0.2, 21.8±0.2, 22.2±0.2, 23.0±0.2, 23.5±0.2, 23.8±0.2, 24.1±0.2, 24.7±0.2, 24.9±0.2, 25.8±0.2, 26.4±0.2, 27.6±0.2, 28.1±0.2, 29±0.2, 29.9±0.2, 30.8±0.2, 31.5±0.2, 31.8±0.2, 32.1±0.2, 33.8±0.2, 34.6±0.2, 35.9±0.2, 36.5±0.2, and 38±0.2. In another preferred embodiment, the crystal Form 22 has an X-ray powder diffraction pattern substantially as shown in Figure 54. In another preferred embodiment, the crystal Form 22 has an NMR spectrum substantially as shown in Figure 53. In another preferred embodiment, the crystal Form 22 has a thermogravimetric curve substantially as shown in Figure 55. In another preferred embodiment, the thermogravimetric test of the crystal Form 22 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 200 to 250 °C (e.g., 220 °C); the second-stage weight loss continues until complete decomposition in the end. In another preferred embodiment, the molar ratio of the compound of Formula I to hydrobromic acid in the crystal Form 22 is 1:0.8-20, for example 1:1, 1:2, 1:3, 1:5, 1:8, 1:10, 1:15, or 1:18. In another preferred embodiment, the phosphate salt crystal form is phosphate salt crystal Form 23, wherein the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 8.0±0.2, 18.5±0.2, 25.8±0.2, and 30.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 8.0±0.2, 16.0±0.2, 17.8±0.2, 18.5±0.2, 19.8±0.2, 24.1±0.2, 24.4±0.2, 24.8±0.2, 25.8±0.2, and 30.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at ten or more (e.g., 11, 12, 13, 14 or 15) 20 values selected from the group consisting of 8.0±0.2, 9.1±0.2, 12.0±0.2, 16.0±0.2, 17.8±0.2, 18.2±0.2, 18.5±0.2, 19.8±0.2, 21.5±0.2, 24.1±0.2, 24.4±0.2, 24.8±0.2, 25.8±0.2, 27.8±0.2, and 30.4±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at the following 20 values: 8.0±0.2, 9.1±0.2, 12.0±0.2, 16.0±0.2, 16.6±0.2, 17.8±0.2, 18.2±0.2, 18.5±0.2, 19.8±0.2, 21.5±0.2, 24.1±0.2, 24.4±0.2, 24.8±0.2, 25.8±0.2, 27.8±0.2, 28.6±0.2, 30.4±0.2. In another preferred embodiment, the crystal Form 23 has an X-ray powder diffraction pattern substantially as shown in Figure 57. In another preferred embodiment, the crystal Form 23 has an NMR spectrum substantially as shown in Figure 56. In another preferred embodiment, the crystal Form 23 has a thermogravimetric curve substantially as shown in Figure 58. In another preferred embodiment, the thermogravimetric test of the crystal Form 23 comprises two weight-loss processes, gradual weight loss occurs from the onset of heating in the first stage, with a termination temperature ranging from 280 to 320 °C (e.g., 300 °C); the second-stage weight loss continues until complete decomposition at the end. In another preferred embodiment, the molar ratio of the compound of Formula I to hydrobromic acid in the crystal Form 23 is 1:0.8-20, for example 1:1, 1:2, 1:3, 1:5, 1:8, 1:10, 1:15, or 1:18. In another preferred embodiment, the nitrate salt crystal form is nitrate salt crystal Form 24, wherein the X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 12.4±0.2, 19.3±0.2, 20.8±0.2, 23.8±0.2, and 27.9±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at six or more (e.g., 7, 8, 10 or 12) 20 values selected from the group consisting of 12.4±0.2, 14.4±0.2, 19.0±0.2, 19.3±0.2, 19.6±0.2, 20.8±0.2, 22.5±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 24.9±0.2, and 27.9±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 18 or 20) 20 values selected from the group consisting of 4.3±0.2, 8.6±0.2, 12.4±0.2, 13.9±0.2, 14.4±0.2, 16.2±0.2, 16.8±0.2, 18.0±0.2, 19.0±0.2, 19.3±0.2, 19.6±0.2, 20.4±0.2, 20.8±0.2, 22.5±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 24.9±0.2, 25.3±0.2, and 27.9±0.2. In another preferred embodiment, the X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at the following 20 values: 4.3±0.2, 8.6±0.2, 12.4±0.2, 12.9±0.2, 13.9±0.2, 14.4±0.2, 16.2±0.2, 16.8±0.2, 17.4±0.2, 18.0±0.2, 19.0±0.2, 19.3±0.2, 19.6±0.2, 20.4±0.2, 20.8±0.2, 22.1±0.2, 22.5±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 24.9±0.2, 25.3±0.2, 26.9±0.2, 27.9±0.2, 28.3±0.2, 30.2±0.2, 31.4±0.2, 32.7±0.2, 33.8±0.2, 34.7±0.2, and 36.2±0.2. In another preferred embodiment, the crystal Form 24 has an X-ray powder diffraction pattern substantially as shown in Figure 60. In another preferred embodiment, the crystal Form 24 has an NMR spectrum substantially as shown in Figure 59. In another preferred embodiment, the molar ratio of the compound of Formula I to hydrobromic acid in the crystal Form 24 is 1:0.8-20, for example 1:1, 1:2, 1:3, 1:5, 1:8, 1:10, 1:15, or 1:18. The second aspect of the present invention provides a method for preparing the salt crystal form of the compound of Formula I according to the first aspect of the present invention, the method comprises steps of: mixing the compound of Formula I with a solvent, then adding a corresponding acid, and further mixing for crystallization or evaporation to obtain the salt crystal form. In another preferred embodiment, the compound of Formula I is a free base of the compound of Formula I, preferably is an amorphous form or a crystal form of the free base. In another preferred embodiment, the solvent is selected from the group consisting of methanol, dichloromethane, acetonitrile, ethyl acetate, acetone, and the combinations thereof. In another preferred embodiment, the acid is selected from the group consisting of oxalic acid, maleic acid, fumaric acid, succinic acid, D-tartaric acid, L-tartaric acid, D-malic acid, L-malic acid, L-glutamic acid, citric acid, benzoic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid. In another preferred embodiment, the acid is in the form of the acid, an aqueous solution of the acid, or a hydrate of the acid. In another preferred embodiment, the molar ratio of the compound of Formula I to the corresponding acid is 1:0.8-2 or 1:5-40, for example 1:0.9, 1:1, 1:1.2, 1:1.5, 1:5, 1:8, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, or 1:37. In another preferred embodiment, the mass-to-volume ratio of the compound of Formula I to the solvent is 1-5 g / L, for example 2.5 g / L. In another preferred embodiment, the method comprises steps of: adding the compound of Formula I into a solvent, mixing to obtain a clear solution, then adding the corresponding acid, further mixing, and performing crystallization or evaporation to obtain the corresponding salt crystal form. The third aspect of the present invention provides a pharmaceutical composition, comprising the salt crystal form of the compound of Formula I according to the first aspect of the present invention, and a pharmaceutically acceptable carrier. The fourth aspect of the present invention provides a use of the salt crystal form of the compound of Formula I according to the first aspect of the present invention for preparing a composition for preventing and / or treating cancer. In another preferred embodiment, the cancer is selected from the group consisting of lung cancer, prostate cancer, colon cancer, and leukemia. It is to be understood that within the scope of the present invention, the above-mentioned respective technical features of the present invention and the respective technical features specifically described hereinafter (e.g., in the Examples) may be combined with one another to constitute new or preferred technical solutions. Due to space limitations, they will not be enumerated one by one herein. DESCRIPTION OF THE DRAWINGS Figure 1 shows the NMR spectrum of oxalate salt crystal Form 1. Figure 2 shows the powder X-ray diffraction pattern of oxalate salt crystal Form 1. Figure 3 shows the TG curve of oxalate crystal Form 1. Figure 4 shows the NMR spectrum of maleate salt crystal Form 2. Figure 5 shows the powder X-ray diffraction pattern of maleate salt crystal Form 2. Figure 6 shows the TG curve of maleate salt crystal Form 2. Figure 7 shows the NMR spectrum of fumarate salt crystal Form 3. Figure 8 shows the powder X-ray diffraction pattern of fumarate salt crystal Form 3. Figure 9 shows the TG curve of fumarate salt crystal Form 3. Figure 10 shows the NMR spectrum of succinate salt crystal Form 4. Figure 11 shows the powder X-ray diffraction pattern of succinate salt crystal Form 4. Figure 12 shows the NMR spectrum of D-tartrate salt crystal Form 5. Figure 13 shows the powder X-ray diffraction pattern of D-tartrate salt crystal Form 5. Figure 14 shows the NMR spectrum of L-tartrate salt crystal Form 6. Figure 15 shows the powder X-ray diffraction pattern of L-tartrate salt crystal Form 6. Figure 16 shows the NMR spectrum of D-malate salt crystal Form 7. Figure 17 shows the powder X-ray diffraction pattern of D-malate salt crystal Form 7. Figure 18 shows the NMR spectrum of L-malate salt crystal Form 8. Figure 19 shows the powder X-ray diffraction pattern of L-malate salt crystal Form 8. Figure 20 shows the NMR spectrum of L-glutamate salt crystal Form 9. Figure 21 shows the powder X-ray diffraction pattern of L-glutamate salt crystal Form 9. Figure 22 shows the NMR spectrum of citrate salt crystal Form 10. Figure 23 shows the powder X-ray diffraction pattern of citrate salt crystal Form 10. Figure 24 shows the NMR spectrum of benzoate salt crystal Form 11. Figure 25 shows the powder X-ray diffraction pattern of benzoate salt crystal Form 11. Figure 26 shows the NMR spectrum of salicylate salt crystal Form 12. Figure 27 shows the powder X-ray diffraction pattern of salicylate salt crystal Form 12. Figure 28 shows the NMR spectrum of methanesulfonate salt crystal Form 13. Figure 29 shows the powder X-ray diffraction pattern of methanesulfonate salt crystal Form 13. Figure 30 shows the TG curve of methanesulfonate salt crystal Form 13. Figure 31 shows the NMR spectrum of ethanesulfonate salt crystal Form 14. Figure 32 shows the powder X-ray diffraction pattern of ethanesulfonate salt crystal Form 14. Figure 33 shows the TG curve of ethanesulfonate crystal Form 14. Figure 34 shows the NMR spectrum of benzenesulfonate salt crystal Form 15. Figure 35 shows the powder X-ray diffraction pattern of benzenesulfonate salt crystal Form 15. Figure 36 shows the TG curve of o benzenesulfonate salt crystal Form 15. Figure 37 shows the NMR spectrum of p-toluenesulfonate salt crystal Form 16. Figure 38 shows the powder X-ray diffraction pattern of p-toluenesulfonate salt crystal Form 16. Figure 39 shows the TG curve of p-toluenesulfonate salt crystal Form 16. Figure 40 shows the NMR spectrum of acetate salt crystal Form 17. Figure 41 shows the powder X-ray diffraction pattern of acetate salt crystal Form 17. Figure 42 shows the NMR spectrum of trifluoroacetate salt crystal Form 18. Figure 43 shows the powder X-ray diffraction pattern of trifluoroacetate salt crystal Form 18. Figure 44 shows the TG curve of trifluoroacetate salt crystal Form 18. Figure 45 shows the NMR spectrum of propionate salt crystal Form 19. Figure 46 shows the powder X-ray diffraction pattern of propionate salt crystal Form 19. Figure 47 shows the NMR spectrum of hydrochloride salt crystal Form 20. Figure 48 shows the powder X-ray diffraction pattern of hydrochloride salt crystal Form 20. Figure 49 shows the TG curve of hydrochloride salt crystal Form 20. Figure 50 shows the NMR spectrum of hydrobromide salt crystal Form 21. Figure 51 shows the powder X-ray diffraction pattern of hydrobromide salt crystal Form 21. Figure 52 shows the TG curve of hydrobromide salt crystal Form 21. Figure 53 shows the NMR spectrum of sulfate salt crystal Form 22. Figure 54 shows the powder X-ray diffraction pattern of sulfate salt crystal Form 22. Figure 55 shows the TG curve of sulfate salt crystal Form 22. Figure 56 shows the NMR spectrum of phosphate salt crystal Form 23. Figure 57 shows the powder X-ray diffraction pattern of phosphate salt crystal Form 23. Figure 58 shows the TG curve of phosphate salt crystal Form 23. Figure 59 shows the NMR spectrum of nitrate salt crystal Form 24. Figure 60 shows the powder X-ray diffraction pattern of nitrate salt crystal Form 24. DETAILED DESCRIPTION OF THE INVENTION The inventors have conducted extensive and in-depth research and have for the first time discovered a acid salt crystal form of plinabulin. The salt crystal form of the present invention exhibits excellent solubility, hygroscopicity and pharmacokinetic properties. The present invention has been completed on this basis. Terms Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the terms “comprise”, “include” and “contain” are used interchangeably, and cover not only closed-ended definitions but also semi-closed-ended and open-ended definitions. In other words, said terms encompass “consisting of” and “consisting essentially of”. As used herein, when employed in reference to a specifically recited numerical value, the term “about” means that the value may vary by no more than 1 % from the recited value. For example, as used herein, the expression “about 100” includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, and the like). Crystal form The present invention provides acid salt crystal forms of a compound of Formula I, the salt crystal form is selected from the group consisting of oxalate salt crystal Form 1, maleate salt crystal Form 2, fumarate salt crystal Form 3, succinate salt crystal Form 4, D-tartrate salt crystal Form 5, L-tartrate salt crystal Form 6, D-malate salt crystal Form 7, L-malate salt crystal Form 8, L-glutamate salt crystal Form 9, citrate salt crystal Form 10, benzoate salt crystal Form 11, salicylate salt crystal Form 12, methanesulfonate salt crystal Form 13, ethanesulfonate salt crystal Form 14, benzenesulfonate salt crystal Form 15, p-toluenesulfonate salt crystal Form 16, acetate salt crystal Form 17, trifluoroacetate salt crystal Form 18, propionate salt crystal Form 19, hydrochloride salt crystal Form 20, hydrobromide salt crystal Form 21, sulfate salt crystal Form 22, phosphate salt crystal Form 23, and nitrate salt crystal Form 24. Compositions and methods of administration The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of one or more salt crystal forms according to the first aspect of the present invention, and a pharmaceutically acceptable carrier. Since the acid salt crystal form of the present invention possesses excellent activity for preventing and / or treating cancer, the crystal form of the present invention can be used for treating, preventing and alleviating cancer. The pharmaceutical composition of the present invention comprises a salt crystal form of the present invention or a pharmaceutically acceptable salt thereof within a safe and effective amount range, together with a pharmaceutically acceptable excipient or carrier. The term “safe and effective amount” means an amount of the crystal form of the present invention which is sufficient to markedly ameliorate the condition without causing any severe side effect. Generally, the pharmaceutical composition contains 1 -2000 mg of the crystal form of the present invention per dosage unit, more preferably 10-1000 mg of the crystal form of the present invention per dosage unit. Preferably, the “dosage unit” is a capsule or a tablet. “Pharmaceutically acceptable carrier” refers to one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must possess sufficient purity and sufficiently low toxicity. “Compatible” herein means that the components of the composition are capable of being blended with the crystal form of the present invention and among themselves without appreciably diminishing its pharmaceutical efficacy. Particular examples of pharmaceutically acceptable carriers include cellulose and derivatives thereof (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate and the like), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil and the like), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol and the like), emulsifiers (e.g., Tween®), wetting agents (e.g., sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like. The pharmaceutical composition is an injection, a capsule, a tablet, a pill, a powder or a granule. There is no particular limitation on the administration mode of the crystal form or pharmaceutical composition of the present invention. Representative administration modes include (but are not limited to) oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipients (or carriers), such as sodium citrate or dicalcium phosphate, or mixed with the following components: (a) filler or bulking agent, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binder, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectant, for example, glycerol; (d) disintegrant, for example, agar-agar, calcium carbonate, potato starch or tapioca starch, alginic acid, some complex silicates, and sodium carbonate; (e) dissolution-retarding agent, for example, paraffin; (f) absorption accelerator, for example, quaternary ammonium compounds; (g) wetting agent, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbent, for example, kaolin; and (i) lubricant, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and the mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agent. Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coating and shell material, such as enteric coating and other materials well-known in the art. They may contain opacifying agent, and the release of the active compound or compound in such composition may take place in a delayed manner at a certain part of the digestive tract. Examples of embedding component which can be employed are polymeric substances and waxes. If necessary, the active compound may also be formulated in microcapsule form with one or more of the above-mentioned excipients. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage forms may contain inert diluent conventionally employed in the art, such as water or other solvents, solubilizer and emulsifier, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oil, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, and the mixtures of these substances, and the like. Besides such inert diluents, the composition may also contain adjuvant such as wetting agent, emulsifying and suspending agent, sweetening, flavoring and perfuming agent. In addition to the active compound, suspension may contain suspending agent, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar, and the mixtures of these substances, and the like. Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or non-aqueous solution, dispersion, suspension or emulsion, and sterile powder for reconstitution into sterile injectable solution or dispersion. Suitable aqueous and non-aqueous carrier, diluent, solvent or excipient include water, ethanol, polyols and the suitable mixtures thereof. Dosage forms of the crystal form of the present invention for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile condition with a physiologically acceptable carrier and any preservative, buffer, or propellant which may be required if necessary. The crystal form of the present invention may be administered alone, or in combination with other pharmaceutically acceptable compounds. The therapeutic method of the present invention may be applied alone, or in combination with other therapeutic modalities or therapeutic agents. When using the pharmaceutical composition, a safe and effective amount of the crystal form of the present invention is administered to a mammal (e.g., human) in need of treatment, wherein the administered dose is a pharmaceutically effective dose. For a human subject weighing 60 kg, the daily dosage is generally 1 -2000 mg, preferably 50-1000 mg. Naturally, the specific dosage should also take into account factors such as administration route, patient health status and the like, all of which fall within the skill of the skilled physician. The main advantages of the present invention include: The salt crystal forms of the present invention possess excellent stability and solubility. The present invention will be further explained below in combination with specific Examples. It should be understood that these Examples are only used to illustrate the present invention and not to limit the scope of the present invention. In the following Examples, the test methods without specific conditions are usually in accordance with conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight. Example 1: Preparation and Characterization of Plinabulin Oxalate Salt (Form 1) 1. Experimental Method 50 mg (0.14 mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or ethyl acetate). The mixture was stirred to obtain a clear solution, followed by addition of 18.3 mg (0.2mmol) of oxalic acid. The mixture was continued to stir until crystals gradually precipitated. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 1 is shown in Figure 1. 1H-NMR (300 MHz, DMSO-d6, ppm): 8 1.387(s, 9H), 6.750 (m, 2H), 7.294 (t, J=7.2, 1H), 7.393 (t, J=7.8, 2H), 7.513 (d, J=7.5, 2H), 7.845 (s, 1H), 12.228(s, 2H). 3. XRD Data The powder X-ray diffraction pattern of Form 1 is shown in Figure 2. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin oxalate salt crystal Form 1 exhibits at least 15 of the diffraction peaks listed below. Twenty-eight 20 values are provided, with the peak positions as follows: 3.9±0.2, 5.2±0.2, 7.7±0.2, 8.4±0.2, 10.3±0.2, 12.5±0.2, 14.2±0.2, 14.6±0.2, 15.3±0.2, 16.1±0.2, 17.2±0.2, 18.3±0.2, 18.8±0.2, 19.1±0.2, 19.4±0.2, 21.5±0.2, 22.7±0.2, 23.1±0.2, 23.5±0.2, 23.9±0.2, 25.0±0.2, 25.4±0.2, 25.8±0.2, 26.5±0.2, 28.0±0.2, 29.0±0.2, 29.9±0.2, and 37.0±0.2. 4. TG Analysis Data The TG curve of Form 1 is shown in Figure 3. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 230 °C; the second stage has an onset temperature of 290 °C, and continues until complete decomposition at the end. Example 2: Preparation and Characterization of Plinabulin Maleate Salt (Form 2) 1. Experimental Method 50 mg (0.14 mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or ethyl acetate). The mixture was stirred to obtain a clear solution, 17.3mg (0.14 mmol) of maleic acid was added, and then stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 2 is shown in Figure 4. 1H NMR (400 MHz, DMSO-d6) 8 12.34 (s, 1H), 12.16 (s, 1H), 10.00 (s, 1H), 7.88 - 7.83 (m, 1H), 7.53 - 7.45 (m, 2H), 7.38 (dd, J = 8.4, 6.9 Hz, 2H), 7.33 - 7.24 (m, 1H), 6.81 (s, 1H), 6.71 (s, 1H), 6.22 (s, 2H), 1.35 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 2 is shown in Figure 5. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin maleate salt crystal Form 2 exhibits at least 13 of the diffraction peaks listed below. Twenty-four 20 values are provided, with the peak positions as follows: 6.7±0.2, 12.5±0.2, 13.4±0.2, 14.6±0.2, 15.0±0.2, 15.6±0.2, 16.0±0.2, 16.5±0.2, 17.8±0.2, 18.5±0.2, 19.4±0.2, 19.8±0.2, 20.1±0.2, 21.6±0.2, 22.3±0.2, 22.7±0.2, 23.5±0.2, 24.8±0.2, 25.4±0.2, 26.0±0.2, 26.8±0.2, 28.5±0.2, 29.4±0.2, and 30.6±0.2. 4. TG Analysis Data The TG curve of Form 2 is shown in Figure 6. First stage: the onset temperature is approximately 200 °C, and the termination temperature is approximately 250 °C; second stage: the onset temperature is approximately 280 °C until complete decomposition at the end. Example 3: Preparation and Characterization of Plinabulin Fumarate Salt (Form 3) 1. Experimental Method 50 mg (0.14 mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, ethyl acetate, or acetone). The mixture was stirred to obtain a clear solution, 17.3 mg (0.14 mmol) of fumaric acid was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 3 is shown in Figure 7. 1H NMR (400 MHz, DMSO-d6) 5 12.33 (s, 1H), 12.17 (s, 1H), 9.99 (s, 1H), 7.85 (s, 1H), 7.49 (dd, J = 7.9, 1.4 Hz, 2H), 7.38 (dd, J = 8.4, 6.9 Hz, 2H), 7.33 - 7.24 (m, 1H), 6.81 (s, 1H), 6.71 (s, 1H), 6.22 (s, 2H), 1.35 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 3 is shown in Figure 8. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin fumarate salt crystal Form 3 exhibits at least 14 of the diffraction peaks listed below. Twenty-six 20 values are provided, with the peak positions as follows: 6.6±0.2, 9.8±0.2,  11.2±0.2,  12.4±0.2,  13.3±0.2,  14.6±0.2,  14.9±0.2,  15.6±0.2,  15.9±0.2, 16.4±0.2, 17.8±0.2, 18.5±0.2, 19.4±0.2, 19.7±0.2, 20.0±0.2, 22.2±0.2, 22.6±0.2, 23.4±0.2, 24.8±0.2, 25.3±0.2, 25.9±0.2, 26.8±0.2, 28.5±0.2, 29.4±0.2, 30.5±0.2, and 33.3±0.2. 4. TG Analysis Data The TG curve of Form 3 is shown in Figure 9. Two weight-loss processes are observed; first stage: the onset temperature is approximately 130°C, and the termination temperature is approximately 260 °C; second stage: the onset temperature is approximately 280 °C until complete decomposition at the end. Example 4: Preparation and Characterization of Plinabulin Succinate Salt (Form 4) 1. Experimental Method 50 mg (0.14 mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or ethyl acetate). The mixture was stirred to obtain a clear solution, 17mg (0.14 mmol) of succinic acid was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 4 is shown in Figure 10. 1H NMR (400 MHz, DMSO-d6) 8 12.29 (s, 1H), 12.21 (s, 1H), 12.10 (s, 2H), 9.98 (s, 1H), 7.81 (d, J = 1.0 Hz, 1H), 7.52 - 7.46 (m, 2H), 7.38 (dd, J = 8.4, 6.9 Hz, 2H), 7.33 - 7.24 (m, 1H), 6.82 (d, J = 0.6 Hz, 1H), 6.71 (s, 1H), 2.38 (s, 6H), 1.35 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 4 is shown in Figure 11. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin succinate salt crystal Form 4 exhibits at least 10 of the diffraction peaks listed below. Eighteen 20 values are provided, with the peak positions as follows: 8.2±0.2, 13.1±0.2, 14.8±0.2, 16.1±0.2, 16.3±0.2, 17.7±0.2, 19.2±0.2, 20.1±0.2, 22.4±0.2, 22.9±0.2, 23.9±0.2, 24.3±0.2, 24.6±0.2, 25.4±0.2, 26.2±0.2, 26.6±0.2, 29.4±0.2, and 31.6±0.2. Example 5: Preparation and Characterization of Plinabulin D-Tartrate Salt (Form 5) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, or acetonitrile). The mixture was stirred to obtain a clear solution. 22 mg of D-tartaric acid was added, and stirring was continued, whereby the system turned into a yellow transparent solution. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 5 is shown in Figure 12. 1H NMR (400 MHz, DMSO-d6) 8 12.30 (s, 1H), 12.22 (s, 1H), 10.00 (s, 1H), 7.82 (s, 1H), 7.52 - 7.46 (m, 2H), 7.42 - 7.34 (m, 2H), 7.33 - 7.24 (m, 1H), 6.82 (s, 1H), 6.71 (s, 1H), 4.99 (s, 2H), 4.26 (s, 2H), 1.35 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 5 is shown in Figure 13. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin D-tartrate salt crystal Form 5 exhibits at least 10 of the diffraction peaks listed below. Seventeen 20 values are provided, with the peak positions as follows: 7.0±0.2, 9.1±0.2,  11.8±0.2,  12.3±0.2,  12.9±0.2,  17.3±0.2,  17.6±0.2,  18.1±0.2,  18.5±0.2, 20.1±0.2, 20.7±0.2, 21.07±0.2, 22.2±0.2, 25.07±0.2, 26.0±0.2, 27.9±0.2, and 28.7±0.2. Example 6: Preparation and Characterization of Plinabulin L-Tartrate Salt (Form 6) 1. Experimental Method 50 mg (0.148 mmol) of plinabulin was added into 30 mL of methanol (or solvent system such as dichloromethane). The mixture was stirred to obtain a clear solution. 22 mg of L-tartaric acid was added, and stirring was continued, whereby the system turned into a yellow transparent solution. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 6 is shown in Figure 14. 1H NMR (400 MHz, DMSO-d6) 8 12.29 (s, 0.5H), 12.23 (d, J = 13.1 Hz, 1H), 12.02 (s, 0.5H), 10.70 (s, 0.5H), 9.98 (s, 0.5H), 7.80 (d, J = 10.4 Hz, 1H), 7.50 (dt, J = 9.2, 3.2 Hz, 2H), 7.38 (dd, J = 8.4, 6.9 Hz, 1H), 7.33 - 7.15 (m, 2H), 6.82 (s, 0.5H), 6.73 (d, J = 14.9 Hz, 1H), 6.48 (s, 0.5H), 1.34 (d, J = 3.5 Hz, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 6 is shown in Figure 15. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin L-tartrate salt crystal Form 6 exhibits at least 21 of the diffraction peaks listed below. Forty 20 values are provided, with the peak positions as follows: 8.2±0.2, 8.6±0.2, 9.2±0.2, 11.2±0.2, 13.1±0.2, 13.9±0.2, 14.1±0.2, 14.8±0.2, 15.5±0.2, 16.1±0.2, 16.3±0.2, 17.6±0.2, 18.5±0.2, 19.2±0.2, 19.4±0.2, 19.8±0.2, 20.9±0.2, 21.2±0.2, 22.4±0.2, 22.9±0.2, 23.4±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.4±0.2, 25.8±0.2, 26.6±0.2, 27.2±0.2, 27.5±0.2, 27.9±0.2, 28.3±0.2, 28.9±0.2, 29.3±0.2, 29.9±0.2, 31.3±0.2, 31.8±0.2, 32.4±0.2, 33.0±0.2, 35.7±0.2, and 38.6±0.2. Example 7: Preparation and Characterization of Plinabulin D-Malate Salt (Form 7) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution. 22.3 mg of D-malic acid was added, and stirring was continued, wherein no obvious change was observed, and the solution remained yellow and transparent. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 7 is shown in Figure 16. 1H NMR (400 MHz, DMSO-d6) d 12.31 - 12.19 (m, 1H), 12.02 (s, 1H), 10.70 (s, 1H), 7.84 -7.76 (m, 1H), 7.59 - 7.49 (m, 1H), 7.49 - 7.46 (m, 1H), 7.38 (t, J = 7.7 Hz, 1H), 7.32 - 7.15 (m, 3H), 6.73 (d, J = 14.9 Hz, 1H), 6.48 (s, 1H), 1.34 (dd, J = 3.6, 0.7 Hz, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 7 is shown in Figure 17. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin D-malate salt crystal Form 7 exhibits at least 20 of the diffraction peaks listed below. Thirty-nine 20 values are provided, with the peak positions as follows: 8.1±0.2, 9.2±0.2,  11.1±0.2,  13.0±0.2,  13.9±0.2,  14.1±0.2,  14.8±0.2,  15.4±0.2,  16.0±0.2, 16.2±0.2, 17.6±0.2, 18.4±0.2, 19.1±0.2, 19.7±0.2, 20.8±0.2, 21.2±0.2, 22.4±0.2, 22.8±0.2, 23.4±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 25.3±0.2, 25.7±0.2, 26.5±0.2, 27.1±0.2, 27.4±0.2, 27.9±0.2, 28.3±0.2, 28.9±0.2, 29.3±0.2, 30.6±0.2, 31.2±0.2, 31.7±0.2, 32.4±0.2, 32.9±0.2, 35.7±0.2, 38.5±0.2, and 38.8±0.2. Example 8: Preparation and Characterization of Plinabulin L-Malate Salt (Form 8) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution, followed by addition of 20.8 mg (0.15 mmol) of L-malic acid. Stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 8 is shown in Figure 18. 1H NMR (400 MHz, DMSO-d6) d 7.81 (s, 1H), 7.49 (d, J = 7.6 Hz, 4H), 7.38 (t, J = 7.4 Hz, 3H), 6.82 (s, 1H), 6.71 (s, 1H), 1.80 (t, J = 7.3 Hz, 9H), 1.35 (s, 28H), 1.20 (s, 6H). 3. XRD Data The powder X-ray diffraction pattern of Form 8 is shown in Figure 19. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin L-malate salt crystal Form 8 exhibits at least 11 of the diffraction peaks listed below. Twenty 20 values are provided, with the peak positions as follows: 10.2±0.2, 13.8±0.2, 20.0±0.2, 20.6±0.2, 21.5±0.2, 22.1±0.2, 23.2±0.2, 23.8±0.2, 24.3±0.2, 25.7±0.2, 26.2±0.2, 27.7±0.2, 28.9±0.2, 30.1±0.2, 31.1±0.2, 33.1±0.2, 33.7±0.2, 35.7±0.2, 38.0±0.2, and 38.7±0.2. Example 9: Preparation and Characterization of Plinabulin L-Glutamate Salt (Form 9) 1. Experimental Method 51 mg (0.151 mmol) of plinabulin was added into 30 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution, followed by addition of 23 mg (0.15 mmol) of L-glutamic acid. Stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 9 is shown in Figure 20. 1H NMR (400 MHz, DMSO-d6) 5 12.23 (d, J = 12.8 Hz, 1H), 12.02 (s, 1H), 10.70 (s, 1H), 7.79 (s, 1H), 7.50 (dt, J = 8.1, 1.2 Hz, 2H), 7.28 - 7.15 (m, 3H), 6.75 (d, J = 0.7 Hz, 1H), 6.48 (s, 1H), 1.34 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 9 is shown in Figure 21. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin L-glutamate salt crystal Form 9 exhibits at least 11 of the diffraction peaks listed below. Twenty 20 values are provided, with the peak positions as follows: 7.3±0.2, 11.2±0.2, 14.7±0.2, 15.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.8±0.2, 20.6±0.2, 22.1±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.9±0.2, 26.4±0.2, 27.5±0.2, 28.6±0.2, 29.2±0.2, 30.4±0.2, and 39.2±0.2. Example 10: Preparation and Characterization of Plinabulin Citrate Salt (Form 10) 1. Experimental Method 51 mg (0.151 mmol) of plinabulin was added into 30 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution. 30 mg (0.14 mmol) of citric acid monohydrate was added, and no obvious change was observed. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 10 is shown in Figure 22. 1H NMR (400 MHz, DMSO-d6) 5 12.25 (t, J = 14.6 Hz, 1H), 12.02 (s, 1H), 10.70 (s, 1H), 7.84 - 7.76 (m, 1H), 7.50 (ddd, J = 5.6, 4.4, 2.7 Hz, 3H), 7.38 (dd, J = 8.4, 6.9 Hz, 1H), 7.32 - 7.15 (m, 3H), 6.48 (s, 1H), 1.34 (d, J = 3.5 Hz, 12H). 3. XRD Data The powder X-ray diffraction pattern of Form 10 is shown in Figure 23. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin citrate salt crystal Form 10 exhibits at least 20 of the diffraction peaks listed below. Thirty-eight 20 values are provided, with the peak positions as follows: 3.5±0.2, 7.3±0.2, 8.1±0.2, 11.2±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 16.0±0.2, 16.3±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 24.8±0.2, 25.3±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 27.9±0.2, 28.6±0.2, 29.2±0.2, 30.4±0.2, 32.0±0.2, 33.0±0.2, 33.9±0.2, 34.1±0.2, 35.3±0.2, 38.6±0.2, and 39.1±0.2. Example 11: Preparation and Characterization of Plinabulin Benzoate Salt (Form 11) 1. Experimental Method 51 mg (0.151 mmol) of plinabulin was added into 30 mL of methanol (or solvent systems such as dichloromethane, or ethyl acetate). The mixture was stirred to obtain a clear solution. 19mg (0.156mmol) of benzoic acid was added, and stirring was continued, with no obvious change being observed. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 11 is shown in Figure 24. 1H NMR (400 MHz, DMSO-d6) 5 10.23 (s, 1H), 7.59 - 7.46 (m, 4H), 7.39 (dd, J = 8.4, 6.9 Hz, 2H), 7.34 - 7.21 (m, 4H), 6.75 (s, 1H), 6.67 (s, 1H), 1.32 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 11 is shown in Figure 25. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin benzoate salt crystal Form 11 exhibits at least 17 of the diffraction peaks listed below. Thirty-two 20 values are provided, with the peak positions as follows: 7.3±0.2, 8.1±0.2,  11.0±0.2,  11.2±0.2,  12.3±0.2,  14.6±0.2,  15.4±0.2,  16.4±0.2,  17.2±0.2, 17.5±0.2, 18.1±0.2, 19.7±0.2, 20.6±0.2, 21.4±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 28.6±0.2, 29.2±0.2, 30.4±0.2, 31.0±0.2, 33.0±0.2, 33.9±0.2, 35.3±0.2, and 39.2±0.2. Example 12: Preparation and Characterization of Plinabulin Salicylate Salt (Form 12) 1. Experimental Method 51 mg (0.151 mmol) of plinabulin was added into 30 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution. 21 mg (0.15 mmol) of salicylic acid was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 12 is shown in Figure 26. 1H NMR (400 MHz, DMSO-d6) 5 12.25 (s, 1H), 12.02 (s, 1H), 10.70 (s, 1H), 7.79 (s, 1H), 7.57 - 7.46 (m, 3H), 7.29 - 7.20 (m, 3H), 7.20 - 7.14 (m, 1H), 6.75 (d, J = 1.3 Hz, 1H), 6.48 (s, 1H), 1.34 (d, J = 1.3 Hz, 11H), 0.94 (d, J = 1.3 Hz, 1H). 3. XRD Data The powder X-ray diffraction pattern of Form 12 is shown in Figure 27. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin salicylate salt crystal Form 12 exhibits at least 18 of the diffraction peaks listed below. Thirty-four 20 values are provided, with the peak positions as follows: 6.2±0.2, 7.3±0.2,  11.2±0.2,  12.3±0.2,  14.6±0.2,  15.4±0.2,  16.4±0.2,  17.1±0.2,  17.4±0.2, 18.1±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 25.4±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 28.5±0.2, 29.2±0.2, 30.4±0.2, 31.0±0.2, 31.5±0.2, 32.0±0.2, 33.0±0.2, 34.0±0.2, 35.3±0.2, and 39.1±0.2. Example 13: Preparation and Characterization of Plinabulin Methanesulfonate Salt (Form 13) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 30 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution. Five drops of methanesulfonic acid were added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 13 is shown in Figure 28. 1H NMR (400 MHz, DMSO-d6) 5 10.22 (s, 1H), 7.53 - 7.46 (m, 2H), 7.39 (dd, J = 8.4, 6.8 Hz, 2H), 7.34 - 7.26 (m, 1H), 6.75 (s, 1H), 6.67 (s, 1H), 2.30 (s, 3H), 1.32 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 13 is shown in Figure 29. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin methanesulfonate salt crystal Form 13 exhibits at least 17 of the diffraction peaks listed below. Thirty-three 20 values are provided, with the peak positions as follows: 9.9±0.2, 12.1±0.2, 14.2±0.2, 14.6±0.2, 15.6±0.2, 16.5±0.2, 18.0±0.2, 18.9±0.2, 19.8±0.2, 20.5±0.2, 21.0±0.2, 21.9±0.2, 23.0±0.2, 23.5±0.2, 23.9±0.2, 24.4±0.2, 24.9±0.2, 26.3±0.2, 26.7±0.2, 27.4±0.2, 27.9±0.2, 28.3±0.2, 28.8±0.2, 29.4±0.2, 29.9±0.2, 30.4±0.2, 31.2±0.2, 31.6±0.2, 33.5±0.2, 34.2±0.2, 35.1±0.2, 37.9±0.2, and 39.2±0.2. 4. TG Analysis Data The TG curve of Form 13 is shown in Figure 30. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 170 °C; second stage: the onset temperature is 270 °C until complete decomposition at the end. Example 14: Preparation and Characterization of Plinabulin Ethanesulfonate Salt (Form 14) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 30 mL of methanol (or solvent systems such as dichloromethane, or acetonitrile). The mixture was stirred to obtain a clear solution. Four drops of ethanesulfonic acid were added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 14 is shown in Figure 31. 1H NMR (400 MHz, DMSO-d6) 5 10.20 (s, 1H), 7.53 - 7.46 (m, 2H), 7.39 (dd, J = 8.4, 6.8 Hz, 2H), 7.34 - 7.25 (m, 1H), 6.75 (s, 1H), 6.68 (s, 1H), 2.38 (q, J = 7.4 Hz, 2H), 1.32 (s, 9H), 1.03 (t, J = 7.4 Hz, 3H). 3. XRD Data The powder X-ray diffraction pattern of Form 14 is shown in Figure 32. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin ethanesulfonate salt crystal Form 14 includes at least 13 of the diffraction peaks listed below. Twenty-four 20 values are provided, with the peak positions as follows: 4.2±0.2, 5.5±0.2, 7.6±0.2, 8.7±0.2, 9.89±0.2, 11.7±0.2, 13.6±0.2, 14.2±0.2, 15.1±0.2, 16.0±0.2, 16.6±0.2, 17.3±0.2, 17.9±0.2, 18.4±0.2, 19.8±0.2, 20.9±0.2, 21.9±0.2, 23.4±0.2, 24.4±0.2, 25.4±0.2, 27.6±0.2, 28.7±0.2, 30.7±0.2, and 37.2±0.2. 4. TG Analysis Data The TG curve of Form 14 is shown in Figure 33. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 120 °C; second stage: the onset temperature is 250 °C until complete decomposition at the end. Example 15: Preparation and Characterization of Plinabulin Benzenesulfonate Salt (Form 15) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, or ethyl acetate). The mixture was stirred to obtain a clear solution. 25 mg (0.4 mmol) of benzenesulfonic acid hydrate was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 15 is shown in Figure 34. 1H NMR (300 MHz, MEOD) 5 8.80 (s, 1H), 7.84-7.81 (q, 2H), 7.52 - 7.37 (m, 7H), 6.99(s, 1H), 6.72(s, 1H), 1.42(s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 15 is shown in Figure 35. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin benzenesulfonate salt crystal Form 15 exhibits at least 16 of the diffraction peaks listed below. Thirty 20 values are provided, with the peak positions as follows: 5.7±0.2, 6.8±0.2, 8.6±0.2, 9.0±0.2, 9.3±0.2, 10.0±0.2, 10.9±0.2, 11.5±0.2, 12.5±0.2, 13.7±0.2, 14.9±0.2, 16.2±0.2, 16.6±0.2, 17.4±0.2, 18.4±0.2, 19.5±0.2, 19.9±0.2, 20.6±0.2, 22.4±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, 25.2±0.2, 26.3±0.2, 27.6±0.2, 28.8±0.2, 29.7±0.2, 30.4±0.2, 36.3±0.2, and 36.7±0.2. 4. TG Analysis Data The TG curve of Form 15 is shown in Figure 36. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 280 °C; second stage: the onset temperature is 280 °C until complete decomposition at the end. Example 16: Preparation and Characterization of Plinabulin p-Toluenesulfonate Salt (Form 16) 1. Experimental Method 50.5 mg (0.150 mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as dichloromethane, or acetonitrile). The mixture was stirred to obtain a clear solution. 36mg (0.209 mmol) of p-toluenesulfonic acid was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 16 is shown in Figure 37. 1H NMR (500 MHz, DMSO-d6) 5 8.97 (s, 1H), 8.28(s, 1H), 7.75- 7.73 (d, J =8 Hz 2H), 7.47 -7.44(q, 4H), 7.37 - 7.34(m, 1H), 7.18 - 7.17 (d, J =8 Hz 2H), 6.93 (s, 1H), 6.81 (s, 1H), 2.36 (s, 6H), 1.42 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 16 is shown in Figure 38. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin p-toluenesulfonate salt crystal Form 16 exhibits at least 13 of the diffraction peaks listed below. Twenty-four 20 values are provided, with the peak positions as follows: 6.3±0.2, 6.6±0.2, 8.5±0.2, 8.8±0.2, 12.7±0.2, 14.3±0.2, 15.1±0.2, 16.2±0.2, 17.0±0.2, 17.7±0.2, 18.5±0.2, 18.8±0.2, 20.0±0.2, 20.4±0.2, 21.5±0.2, 22.4±0.2, 23.6±0.2, 24.0±0.2, 24.5±0.2, 26.2±0.2, 27.4±0.2, 28.4±0.2, 29.2±0.2, and 31.5±0.2. 4. TG Analysis Data The TG curve of Form 16 is shown in Figure 39. First stage: gradual weight loss occurs from the onset of heating until complete decomposition at the end. Example 17: Preparation and Characterization of Plinabulin Acetate Salt (Form 17) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 35 mL of methanol (or solvent systems such as acetonitrile, acetone, or dichloromethane). The mixture was stirred to obtain a clear solution. 15 mg (0.25 mmol) of acetic acid was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 17 is shown in Figure 40. 1H NMR (400 MHz, DMSO-d6) 5 12.27 (d, J = 15.1 Hz, 1H), 12.21 (s, 1H), 7.80 (dd, J = 10.5, 0.7 Hz, 1H), 7.50 (ddd, J = 7.4, 4.7, 1.4 Hz, 2H), 7.38 (dd, J = 8.4, 6.9 Hz, 1H), 7.33 - 7.14 (m, 2H), 6.82 (d, J = 0.7 Hz, 1H), 6.77 - 6.69 (m, 1H), 1.34 (d, J = 3.5 Hz, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 17 is shown in Figure 41. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin acetate salt crystal Form 17 exhibits at least 21 of the diffraction peaks listed below. Thirty-nine 20 values are provided, with the peak positions as follows: 8.2±0.2, 9.2±0.2,  11.2±0.2,  13.1±0.2,  13.9±0.2,  14.1±0.2,  14.8±0.2,  15.5±0.2,  16.0±0.2, 16.3±0.2, 17.6±0.2, 18.4±0.2, 19.1±0.2, 19.8±0.2, 20.8±0.2, 21.2±0.2, 22.4±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.3±0.2, 25.7±0.2, 26.5±0.2, 27.1±0.2, 27.4±0.2, 27.9±0.2, 28.3±0.2, 28.9±0.2, 29.3±0.2, 30.6±0.2, 31.2±0.2, 31.7±0.2, 32.4±0.2, 33.0±0.2, 34.6±0.2, 35.7±0.2, 37.2±0.2, and 38.5±0.2. Example 18: Preparation and Characterization of Plinabulin Trifluoroacetate Salt (Form 18) 1. Experimental Method 50 mg (0.148 mmol) of plinabulin was dissolved in 40 mL of methanol (or solvent systems such as dichloromethane, or acetonitrile). The mixture was stirred to obtain a clear solution. Three drops of trifluoroacetic acid were added, and stirring was continued, with forming milky-white floccule, and the color of the solution lightening to nearly colorless. The sample was obtained by evaporation. 2. NMR Data The NMR spectrum of Form 18 is shown in Figure 42. 1H NMR (400 MHz, DMSO-d6) 5 12.57 (s, 1H), 11.96 (s, 1H), 10.06 (s, 1H), 8.02 (s, 1H), 7.49 (d, J = 7.4 Hz, 2H), 7.38 (s, 1H), 7.29 (s, 1H), 6.77 (s, 1H), 6.73 (s, 1H), 1.34 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 18 is shown in Figure 43. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin trifluoroacetate salt crystal Form 18 exhibits at least 18 of the diffraction peaks listed below. Thirty-five 20 values are provided, with the peak positions as follows: 6.7±0.2, 9.3±0.2,  10.5±0.2,  13.6±0.2,  14.8±0.2,  15.5±0.2,  17.0±0.2,  17.6±0.2,  18.1±0.2, 18.6±0.2, 19.6±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2, 22.3±0.2, 22.9±0.2, 23.5±0.2, 23.9±0.2, 24.4±0.2, 24.7±0.2, 25.4±0.2, 26.1±0.2, 26.9±0.2, 27.4±0.2, 28.0±0.2, 28.7±0.2, 29.2±0.2, 29.9±0.2, 31.1±0.2, 31.7±0.2, 32.8±0.2, 34.5±0.2, 35.9±0.2, 37.0±0.2, and 37.8±0.2. 4. TG Analysis Data The TG curve of Form 18 is shown in Figure 44. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 250 °C; second stage: the onset temperature is 250 °C until complete decomposition at the end. Example 19: Preparation and Characterization of Plinabulin Propionate Salt (Form 19) 1. Experimental Method 50 mg (0.148 mmol) of plinabulin was dissolved in 20 mL of methanol (or solvent systems such as dichloromethane, acetonitrile, acetone). The mixture was stirred to obtain a yellow transparent clear solution. Six drops of propionic acid were added, and stirring was continued, with no obvious change being observed. The sample was obtained by evaporation. 2. NMR Data The NMR spectrum of Form 19 is shown in Figure 45. 1H NMR (400 MHz, DMSO-d6) 5 12.02 (s, 1H), 10.70 (s, 1H), 7.78 (s, 1H), 7.66 - 7.39 (m, 2H), 7.37 - 7.04 (m, 3H), 6.75 (d, J = 0.6 Hz, 1H), 6.48 (s, 1H), 1.34 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 19 is shown in Figure 46. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin propionate salt crystal Form 19 exhibits at least 16 of the diffraction peaks listed below. Thirty 20 values are provided, with the peak positions as follows: 7.3±0.2, 11.2±0.2, 14.6±0.2, 15.4±0.2, 16.4±0.2, 17.2±0.2, 17.4±0.2, 18.0±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 25.7±0.2, 26.3±0.2, 26.6±0.2, 27.5±0.2, 28.5±0.2, 29.2±0.2, 30.4±0.2, 31.6±0.2, 32.0±0.2, 33.0±0.2, 34.1±0.2, 35.3±0.2, 36.9±0.2, and 39.1±0.2. Example 20: Preparation and Characterization of Plinabulin Hydrochloride Salt (Form 20) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 25 mL of methanol (or solvent systems such as acetonitrile, or dichloromethane). The mixture was stirred to obtain a clear solution. Four drops of 35 % aqueous hydrochloric acid solution were added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 20 is shown in Figure 47. 1H NMR (400 MHz, DMSO-d6) 8 11.52 (s, 1H), 10.21 (s, 1H), 8.41 (s, 1H), 7.53 - 7.46 (m, 2H), 7.39 (t, J = 7.6 Hz, 3H), 7.34 - 7.25 (m, 1H), 6.75 (s, 1H), 6.68 (s, 1H), 1.32 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 20 is shown in Figure 48. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin hydrochloride salt crystal Form 20 exhibits at least 17 of the diffraction peaks listed below. Thirty-two 20 values are provided, with the peak positions as follows: 4.6±0.2, 9.1±0.2,  12.2±0.2,  13.7±0.2,  14.5±0.2,  15.1±0.2,  17.7±0.2,  18.2±0.2,  19.0±0.2, 19.7±0.2, 21.0±0.2, 21.6±0.2, 22.8±0.2, 23.3±0.2, 24.1±0.2, 24.6±0.2, 24.9±0.2, 26.2±0.2, 26.6±0.2, 27.2±0.2, 27.5±0.2, 28.5±0.2, 28.8±0.2, 29.7±0.2, 30.2±0.2, 30.6±0.2, 31.7±0.2, 32.2±0.2, 33.0±0.2, 35.3±0.2, 36.0±0.2, and 38.8±0.2. 4. TG Analysis Data The TG curve of Form 20 is shown in Figure 49. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 150°C; second stage: the termination temperature is approximately 260 °C; third stage: the onset temperature is 280 °C until complete decomposition at the end. Example 21: Preparation and Characterization of Plinabulin Hydrobromide Salt (Form 21) 1. Experimental Method 50mg (0.148mmol) of plinabulin was added into 20 mL of methanol (or solvent systems such as acetonitrile, or dichloromethane). The mixture was stirred to obtain a clear solution. One drop of 48 % hydrobromic acid solution was added, and stirring was continued. The resulting mixture was filtered, allowed to stand, and subjected to evaporation to afford the sample. 2. NMR Data The NMR spectrum of Form 21 is shown in Figure 50. 1H NMR (400 MHz, DMSO-d6) 8 10.22 (s, 1H), 7.53 - 7.46 (m, 2H), 7.39 (dd, J = 8.4, 6.9 Hz, 2H), 7.34 - 7.25 (m, 1H), 6.75 (s, 1H), 6.67 (s, 1H), 1.32 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 21 is shown in Figure 51. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin hydrobromide salt crystal Form 21 exhibits at least 21 of the diffraction peaks listed below. Forty-one 20 values are provided, with the peak positions as follows: 9.0±0.2, 11.2±0.2, 11.4±0.2, 12.1±0.2, 12.8±0.2, 13.5±0.2, 14.8±0.2, 15.9±0.2, 16.1±0.2, 17.2±0.2, 17.7±0.2, 18.9±0.2, 19.4±0.2, 19.7±0.2, 20.2±0.2, 20.9±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, 24.7±0.2, 25.1±0.2, 25.5±0.2, 26.1±0.2, 26.3±0.2, 26.8±0.2, 27.3±0.2, 27.6±0.2, 28.3±0.2, 28.8±0.2, 29.7±0.2, 29.9±0.2, 30.5±0.2, 31.5±0.2, 32.3±0.2, 32.6±0.2, 32.9±0.2, 33.4±0.2, 34.6±0.2, 36.6±0.2, 37.0±0.2, and 38.6±0.2. 4. TG Analysis Data The TG curve of Form 21 is shown in Figure 52. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 300 °C; second stage: a termination temperature of approximately 310°C until complete decomposition at the end. Example 22: Preparation and Characterization of Plinabulin Sulfate Salt (Form 22) 1. Experimental Method 50.7mg of plinabulin was dissolved in 16 mL of methanol (or solvent systems such as acetonitrile, or dichloromethane). The mixture was stirred to yield a yellow transparent clear solution. Three drops of sulfuric acid were added, and stirring was continued, wherein the color of the system faded to pale-yellow transparent. 2. NMR Data The NMR spectrum of Form 22 is shown in Figure 53. 1H NMR (400 MHz, DMSO-d6) 5 10.25 (s, 1H), 7.53 - 7.46 (m, 2H), 7.39 (dd, J = 8.4, 6.8 Hz, 2H), 7.34 - 7.26 (m, 1H), 6.76 (s, 1H), 6.65 (s, 1H), 1.32 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 22 is shown in Figure 54. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin sulfate salt crystal Form 22 exhibits at least 20 of the diffraction peaks listed below. Thirty-eight 20 values are provided, with the peak positions as follows: 4.3±0.2, 8.4±0.2,  10.5±0.2, 12.4±0.2, 14.4±0.2,  14.7±0.2,  15.3±0.2, 16.4±0.2, 16.8±0.2, 17.2±0.2, 18.3±0.2, 19.1±0.2, 19.3±0.2, 20.5±0.2, 21.0±0.2, 21.8±0.2, 22.2±0.2, 23.0±0.2, 23.5±0.2, 23.8±0.2, 24.1±0.2, 24.7±0.2, 24.9±0.2, 25.8±0.2, 26.4±0.2, 27.6±0.2, 28.1±0.2, 29±0.2, 29.9±0.2, 30.8±0.2, 31.5±0.2, 31.8±0.2, 32.1±0.2, 33.8±0.2, 34.6±0.2, 35.9±0.2, 36.5±0.2, and 38±0.2. 4. TG Analysis Data The TG curve of Form 22 is shown in Figure 55. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 220 °C; second stage: until complete decomposition at the end. Example 23: Preparation and Characterization of Plinabulin Phosphate Salt (Form 23) 1. Experimental Method 50.1mg of plinabulin was dissolved in 17 mL of methanol (or solvent systems such as acetonitrile, or dichloromethane). The mixture was stirred to obtain a clear solution. Three drops of phosphoric acid were added, and stirring was continued, with no obvious change. 2. NMR Data The NMR spectrum of Form 23 is shown in Figure 56. 1H NMR (400 MHz, DMSO-d6) 5 7.81 (t, J = 0.9 Hz, 1H), 7.52 - 7.45 (m, 2H), 7.38 (t, J = 7.7 Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 6.82 (d, J = 0.6 Hz, 1H), 6.71 (s, 1H), 1.35 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 23 is shown in Figure 57. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin phosphate salt crystal Form 23 of exhibits at least 9 of the diffraction peaks listed below. Seventeen 20 values are provided, with the peak positions as follows: 8.0±0.2, 9.1±0.2,  12.0±0.2, 16.0±0.2, 16.6±0.2,  17.8±0.2,  18.2±0.2, 18.5±0.2, 19.8±0.2, 21.5±0.2, 24.1±0.2, 24.4±0.2, 24.8±0.2, 25.8±0.2, 27.8±0.2, 28.6±0.2, and 30.4±0.2. 4. TG Analysis Data The TG curve of Form 23 is shown in Figure 58. First stage: gradual weight loss occurs from the onset of heating, with a termination temperature of approximately 300 °C; second stage: until complete decomposition at the end. Example 24: Preparation and Characterization of Plinabulin Nitrate Salt (Form 24) 1. Experimental Method 50mg of plinabulin was dissolved in 15 mL of methanol (or other solvent systems such as dichloromethane, acetonitrile, or acetone). The mixture was stirred to obtain a clear solution. Two drops of nitric acid were added, and stirring was continued, with no obvious change. The sample was obtained by evaporation. 2. NMR Data The NMR spectrum of Form 24 is shown in Figure 59. 1H NMR (400 MHz, DMSO-d6) 5 10.21 (s, 1H), 7.53 - 7.46 (m, 2H), 7.39 (dd, J = 8.4, 6.8 Hz, 2H), 7.34 - 7.26 (m, 1H), 6.75 (s, 1H), 6.68 (s, 1H), 1.32 (s, 9H). 3. XRD Data The powder X-ray diffraction pattern of Form 24 is shown in Figure 60. In the X-ray powder diffraction pattern obtained at room temperature of 25 °C with Cu-Ka radiation, plinabulin nitrate salt crystal Form 24 exhibits at least 23 of the diffraction peaks listed below. Thirty-one 20 values are provided, with the peak positions as follows: 4.3±0.2, 8.6±0.2,  12.4±0.2, 12.9±0.2, 13.9±0.2,  14.4±0.2,  16.2±0.2, 16.8±0.2, 17.4±0.2, 18.0±0.2, 19.0±0.2, 19.3±0.2, 19.6±0.2, 20.4±0.2, 20.8±0.2, 22.1±0.2, 22.5±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 24.9±0.2, 25.3±0.2, 26.9±0.2, 27.9±0.2, 28.3±0.2, 30.2±0.2, 31.4±0.2, 32.7±0.2, 33.8±0.2, 34.7±0.2, and 36.2±0.2. Test Example 1 Solubility tests were performed on the plinabulin salt crystal forms from the above Examples. Methanol was added incrementally to 1 mg of each above salt crystal form, and the volume of methanol required for complete dissolution of the salt crystal form was determined. The results are shown in Table 1 below. Table 1 Solubility Test Results of Salt Crystal Forms in the Examples Name (Acid) Crystal Form Sample Dosage Solvent (Methanol) Oxalic acid Form 1 1 mg 0.65 ml Maleic acid Form 2 1 mg 1.4 ml L-malic acid Form 8 1 mg 1 ml Methanesulfonic acid Form 13 1 mg Insoluble in 2 mL Ethanesulfonic acid Form 14 1 mg 1 ml Benzenesulfonic acid Form 15 1 mg 1.2 ml p-Toluenesulfonic acid Form 16 1 mg Insoluble in 2 mL Trifluoroacetic acid Form 18 1 mg 0.5ml Hydrochloric acid Form 20 1 mg 2 ml Hydrobromic acid Form 21 1 mg 0.5 ml Sulfuric acid Form 22 1 mg Insoluble in 2 mL Phosphoric acid Form 23 1 mg Insoluble in 2 mL It can be seen that oxalate, trifluoroacetate and hydrobromide salts exhibit excellent solubility. All documents cited in the present invention are incorporated herein by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference. Furthermore, it should be understood that various modifications or variations may be made by those skilled in the art upon reading the foregoing teaching content of the present invention, and such equivalent forms shall also fall within the scope defined by the appended claims of the present application.

Claims

1. A salt crystal form of a compound of Formula I, owherein, the salt crystal form is selected from the group consisting of oxalate salt crystal form, maleate salt crystal form, fumarate salt crystal form, succinate salt crystal form, D-tartrate salt crystal form, L-tartrate salt crystal form, D-malate salt crystal form, L-malate salt crystal form, L-glutamate salt crystal form, citrate salt crystal form, benzoate salt crystal form, salicylate salt crystal form, methanesulfonate salt crystal form, ethanesulfonate salt crystal form, benzenesulfonate salt crystal form, p-toluenesulfonate salt crystal form, acetate salt crystal form, trifluoroacetate salt crystal form, propionate salt crystal form, hydrochloride salt crystal form, hydrobromide salt crystal form, sulfate salt crystal form, phosphate salt crystal form, and nitrate salt crystal form.

2. The salt crystal form according to claim 1, whereinthe oxalate salt crystal form is oxalate salt crystal Form 1, wherein the X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at three or more (e.g., 4, or 5) 20 values selected from the group consisting of 10.3±0.2, 12.5±0.2, 23.9±0.2, 25.4±0.2, and 29.0±0.2;the maleate salt crystal form is maleate salt crystal Form 2, wherein the X-ray powder diffraction pattern of the crystal Form 2 includes diffraction peaks at 20 values selected from the group consisting of 6.7±0.2, 16.5±0.2, 22.3±0.2, and 25.4±0.2;the fumarate salt crystal form is fumarate salt crystal Form 3, wherein the X-ray powder diffraction pattern of the crystal Form 3 includes diffraction peaks at 20 values selected from the group consisting of 6.6±0.2, 16.4±0.2, 20.0±0.2, 22.2±0.2, and 25.3±0.2;the succinate salt crystal form is succinate salt crystal Form 4, wherein the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 20.1±0.2, 26.2±0.2, and 31.6±0.2;the D-tartrate salt crystal form is D-tartrate salt crystal Form 5, wherein the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 7.0±0.2, 18.5±0.2, 22.2±0.2, 25.07±0.2, and 26.0±0.2;the L-tartrate salt crystal form is L-tartrate salt crystal Form 6, wherein the X-ray powder diffraction pattern of the crystal Form 6 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 16.1±0.2, 19.2±0.2, 22.9±0.2, 23.8±0.2, 24.2±0.2, 25.4±0.2, 26.6±0.2, and 29.3±0.2;the D-malate salt crystal form is D-malate salt crystal Form 7, wherein the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at 20 values selected from the group consisting of 8.1±0.2, 23.8±0.2, 24.2±0.2, and 24.4±0.2;the L-malate salt crystal form is L-malate salt crystal Form 8, wherein the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 10.2±0.2, 20.0±0.2, 20.6±0.2, 33.7±0.2, and 35.7±0.2;the L-glutamate salt crystal form is L-glutamate salt crystal Form 9, wherein the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 19.8±0.2, 22.5±0.2, and 23.1±0.2;the citrate salt crystal form is citrate salt crystal Form 10, wherein the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.1±0.2, 19.7±0.2, 23.1±0.2, and 23.8±0.2;the benzoate salt crystal form is benzoate salt crystal Form 11, wherein the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 23.1±0.2, and 23.8±0.2;the salicylate salt crystal form is salicylate salt crystal Form 12, wherein the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.1±0.2, 19.7±0.2, 23.1±0.2, and 27.5±0.2;the methanesulfonate salt crystal form is methanesulfonate salt crystal Form 13, wherein the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 12.1±0.2, 15.6±0.2, 19.8±0.2, 23.0±0.2, and 26.3±0.2;the ethanesulfonate salt crystal form is ethanesulfonate salt crystal Form 14, wherein the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 5.5±0.2, 9.89±0.2, 20.9±0.2, 23.4±0.2, and 25.4±0.2;the benzenesulfonate salt crystal form is benzenesulfonate salt crystal Form 15, wherein the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 5.7±0.2, 16.2±0.2, 17.4±0.2, 18.4±0.2, and 22.8±0.2;the p-toluenesulfonate salt crystal form is p-toluenesulfonate salt crystal Form 16, wherein the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 6.6±0.2, 15.1±0.2, 16.2±0.2, 21.5±0.2, and 24.5±0.2;the acetate salt crystal form is acetate salt crystal Form 17, wherein the X-ray powder diffraction pattern of the crystal Form 17 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 16.0±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.3±0.2, 26.5±0.2, and 29.3±0.2;the trifluoroacetate salt crystal form is trifluoroacetate salt crystal Form 18, wherein the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 9.3±0.2, 17.0±0.2, 18.6±0.2, and 25.4±0.2;the propionate salt crystal form is propionate salt crystal Form 19, wherein the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 17.4±0.2, 22.5±0.2, and 23.1±0.2 ;the hydrochloride salt crystal form is hydrochloride salt crystal Form 20, wherein theX-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 12.2±0.2, 13.7±0.2, 21.0±0.2, 21.6±0.2, and 22.8±0.2;the hydrobromide salt crystal form is hydrobromide salt crystal Form 21, wherein the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at three or more (e.g., 4, 5 or 6) 20 values selected from the group consisting of 11.2±0.2, 17.7±0.2, 19.7±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, and 24.7±0.2;the sulfate salt crystal form is sulfate salt crystal Form 22, wherein the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 4.3±0.2, 12.4±0.2, 20.5±0.2, and 23.5±0.2 ;the phosphate salt crystal form is phosphate salt crystal Form 23, wherein the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at three or more (e.g., 4) 20 values selected from the group consisting of 8.0±0.2, 18.5±0.2, 25.8±0.2, and 30.4±0.2; and / orthe nitrate salt crystal form is nitrate salt crystal Form 24, wherein the X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at three or more (e.g., 4 or 5) 20 values selected from the group consisting of 12.4±0.2, 19.3±0.2, 20.8±0.2, 23.8±0.2, and 27.9±0.2.

3. The salt crystal form according to claim 2, whereinthe X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at five or more (e.g., 6, 7, 8, or 9) 20 values selected from the group consisting of 5.2±0.2, 10.3±0.2, 12.5±0.2, 16.1±0.2, 18.3±0.2, 19.4±0.2, 22.7±0.2, 23.1±0.2, 23.9±0.2, 25.4±0.2, 25.8±0.2, and 29.0±0.2;the X-ray powder diffraction pattern of the crystal Form 2 includes diffraction peaks at 20 values selected from the group consisting of 6.7±0.2, 16.5±0.2, 18.5±0.2, 19.4±0.2, 19.8±0.2, 20.1±0.2, and 29.4±0.2;the X-ray powder diffraction pattern of the crystal Form 3 includes diffraction peaks at seven or more 20 values selected from the group consisting of 6.6±0.2, 12.4±0.2, 15.9±0.2, 16.4±0.2, 18.5±0.2, 19.7±0.2, 20.0±0.2, 22.2±0.2, 23.4±0.2, 24.8±0.2, 25.3±0.2, 28.5±0.2, and 29.4±0.2;the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 20.1±0.2, 23.9±0.2, 24.3±0.2, 26.2±0.2, 26.6±0.2, 29.4±0.2, and 31.6±0.2;the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9, or 10) 20 values selected from the group consisting of 7.0±0.2, 9.1±0.2, 12.9±0.2, 17.6±0.2, 18.1±0.2, 18.5±0.2, 20.1±0.2, 22.2±0.2, 25.07±0.2, and 26.0±0.2;the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at five or more (e.g., 6, 7, 8, or 9) 20 values selected from the group consisting of 8.1±0.2, 13.0±0.2, 16.2±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 26.5±0.2, and 29.3±0.2;the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at five or more (e.g., 6, 7, 8, 9 or 10) 20 values selected from the group consisting of 10.2±0.2, 20.0±0.2, 20.6±0.2, 21.5±0.2, 22.1±0.2, 24.3±0.2, 26.2±0.2, 28.9±0.2, 33.7±0.2, and 35.7±0.2;the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at 20values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.7±0.2, 17.2±0.2, 17.5±0.2, 19.8±0.2, 20.6±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, and 27.5±0.2;the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 8.1±0.2, 17.1±0.2, 17.4±0.2, 19.7±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 27.5±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.2±0.2, 17.5±0.2, 19.7±0.2,20.6±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, and 27.5±0.2;the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 17.1±0.2, 17.4±0.2, 19.7±0.2,20.6±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 27.5±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at six or more (e.g., 7, 8, 10 or 12) 20 values selected from the group consisting of 9.9±0.2, 12.1±0.2, 15.6±0.2, 16.5±0.2, 18.0±0.2, 18.9±0.2, 19.8±0.2, 20.5±0.2, 21.0±0.2, 23.0±0.2, 23.9±0.2, 24.9±0.2, and 26.3±0.2;the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at six or more (e.g., 8, 10, 12 or 13) 20 values selected from the group consisting of 5.5±0.2, 8.7±0.2, 9.89±0.2, 11.7±0.2, 15.1±0.2, 16.6±0.2, 17.3±0.2, 18.4±0.2, 20.9±0.2, 21.9±0.2,23.4±0.2, 25.4±0.2, and 27.6±0.2;the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at six or more (e.g., 8, 9, 10 or 12) 20 values selected from the group consisting of 5.7±0.2, 13.7±0.2, 14.9±0.2, 16.2±0.2, 16.6±0.2, 17.4±0.2, 18.4±0.2, 22.4±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, and 25.2±0.2;the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 6.6±0.2, 8.5±0.2, 8.8±0.2, 14.3±0.2, 15.1±0.2, 16.2±0.2, 21.5±0.2, 23.6±0.2, 24.5±0.2, and 27.4±0.2;the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at 6 or more (e.g., 7, 8, or 9) 20 values selected from the group consisting of 9.3±0.2, 10.5±0.2, 17.0±0.2, 18.6±0.2, 20.5±0.2, 21.1±0.2, 23.9±0.2, 25.4±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.6±0.2, 17.2±0.2,17.4±0.2, 19.7±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, and 27.5±0.2;the X-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 4.6±0.2, 9.1±0.2, 12.2±0.2, 13.7±0.2, 21.0±0.2, 21.6±0.2, 22.8±0.2, 23.3±0.2, 24.1±0.2, and 28.8±0.2;the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at six or more (e.g., 8, 10, 12 or 13) 20 values selected from the group consisting of 11.2±0.2, 11.4±0.2, 14.8±0.2, 17.7±0.2, 19.7±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, 24.7±0.2, 26.1±0.2, 27.6±0.2, 28.3±0.2, and 29.9±0.2;the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 4.3±0.2, 8.4±0.2, 12.4±0.2, 14.4±0.2, 16.8±0.2, 20.5±0.2, 23.5±0.2, 23.8±0.2, 25.8±0.2, and 33.8±0.2;the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at six or more (e.g., 7, 8, 9 or 10) 20 values selected from the group consisting of 8.0±0.2,16.0±0.2, 17.8±0.2, 18.5±0.2, 19.8±0.2, 24.1±0.2, 24.4±0.2, 24.8±0.2, 25.8±0.2, and 30.4±0.2; and / orthe X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at six or more (e.g., 7, 8, 10 or 12) 20 values selected from the group consisting of 12.4±0.2, 14.4±0.2, 19.0±0.2, 19.3±0.2, 19.6±0.2, 20.8±0.2, 22.5±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 24.9±0.2, and 27.9±0.2.

4. The salt crystal form according to claim 2, whereinthe X-ray powder diffraction pattern of the crystal Form 1 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16, or 18) 20 values selected from the group consisting of 5.2±0.2, 8.4±0.2, 10.3±0.2, 12.5±0.2, 14.2±0.2, 14.6±0.2, 15.3±0.2, 16.1±0.2, 17.2±0.2, 18.3±0.2,19.1±0.2, 19.4±0.2, 22.7±0.2, 23.1±0.2, 23.5±0.2, 23.9±0.2, 25.4±0.2, 25.8±0.2, and 29.0±0.2;the X-ray powder diffraction pattern of the crystal Form 4 includes diffraction peaks at ten or more (e.g., 11, 12, 13, 14 or 15) 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 16.3±0.2, 17.7±0.2, 19.2±0.2, 20.1±0.2, 22.9±0.2, 23.9±0.2, 24.3±0.2, 24.6±0.2, 25.4±0.2, 26.2±0.2, 26.6±0.2, 29.4±0.2, and 31.6±0.2;the X-ray powder diffraction pattern of the crystal Form 5 includes diffraction peaks at ten or more (e.g., 11, 12, 13, 14 or 15) 20 values selected from the group consisting of 7.0±0.2, 9.1±0.2, 11.8±0.2, 12.3±0.2, 12.9±0.2, 17.3±0.2, 17.6±0.2, 18.1±0.2, 18.5±0.2, 20.1±0.2,22.2±0.2, 25.07±0.2, 26.0±0.2, and 27.9±0.2;the X-ray powder diffraction pattern of the crystal Form 6 includes diffraction peaks at 16 or more 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 14.8±0.2, 15.5±0.2, 16.1±0.2, 16.3±0.2, 17.6±0.2, 19.2±0.2, 19.4±0.2, 22.4±0.2, 22.9±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.4±0.2, 26.6±0.2, 27.5±0.2, 29.3±0.2, 31.8±0.2, and 33.0±0.2;the X-ray powder diffraction pattern of the crystal Form 7 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 17) 20 values selected from the group consisting of 8.1±0.2, 13.0±0.2, 16.0±0.2, 16.2±0.2, 17.6±0.2, 19.1±0.2, 19.7±0.2, 20.8±0.2, 22.4±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.4±0.2, 25.3±0.2, 26.5±0.2, and 29.3±0.2;the X-ray powder diffraction pattern of the crystal Form 8 includes diffraction peaks at ten or more (e.g., 12, 13, 14, 15 or 16) 20 values selected from the group consisting of 10.2±0.2, 20.0±0.2, 20.6±0.2, 21.5±0.2, 22.1±0.2, 23.8±0.2, 24.3±0.2, 25.7±0.2, 26.2±0.2, 28.9±0.2, 30.1±0.2, 31.1±0.2, 33.1±0.2, 33.7±0.2, 35.7±0.2, and 38.0±0.2;the X-ray powder diffraction pattern of the crystal Form 9 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.7±0.2, 15.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.8±0.2, 20.6±0.2, 22.1±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.9±0.2, 26.4±0.2, 27.5±0.2, 28.6±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 10 includes diffraction peaks at 18 or more 20 values selected from the group consisting of 7.3±0.2, 8.1±0.2, 11.2±0.2, 13.0±0.2, 14.6±0.2, 15.4±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.2±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.2±0.2, 24.8±0.2, 26.6±0.2, 27.5±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 11 includes diffraction peaks at 18 or more 20 values selected from the group consisting of 7.3±0.2, 11.0±0.2, 11.2±0.2, 14.6±0.2, 15.4±0.2, 17.2±0.2, 17.5±0.2, 18.1±0.2, 19.7±0.2, 20.6±0.2, 21.4±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.4±0.2, 24.8±0.2, 27.5±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 12 includes diffraction peaks at 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 12.3±0.2, 14.6±0.2, 15.4±0.2, 17.1±0.2, 17.4±0.2, 18.1±0.2, 19.7±0.2, 20.6±0.2, 22.0±0.2, 22.4±0.2, 23.1±0.2, 23.8±0.2, 24.8±0.2, 25.7±0.2, 27.5±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 13 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 9.9±0.2, 12.1±0.2, 15.6±0.2, 16.5±0.2, 18.0±0.2, 18.9±0.2, 19.8±0.2, 20.5±0.2, 21.0±0.2, 21.9±0.2, 23.0±0.2, 23.5±0.2, 23.9±0.2, 24.9±0.2, 26.3±0.2, 26.7±0.2, 27.9±0.2, 28.3±0.2, 28.8±0.2, and 31.6±0.2;the X-ray powder diffraction pattern of the crystal Form 14 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 5.5±0.2, 8.7±0.2, 9.89±0.2, 11.7±0.2, 13.6±0.2, 14.2±0.2, 15.1±0.2, 16.0±0.2, 16.6±0.2, 17.3±0.2,17.9±0.2, 18.4±0.2, 19.8±0.2, 20.9±0.2, 21.9±0.2, 23.4±0.2, 24.4±0.2, 25.4±0.2, and 27.6±0.2;the X-ray powder diffraction pattern of the crystal Form 15 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 5.7±0.2, 6.8±0.2, 8.6±0.2, 10.9±0.2,  12.5±0.2, 13.7±0.2, 14.9±0.2,  16.2±0.2,  16.6±0.2, 17.4±0.2,18.4±0.2, 19.5±0.2, 19.9±0.2, 22.4±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, and 25.2±0.2;the X-ray powder diffraction pattern of the crystal Form 16 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 17) 20 values selected from the group consisting of 6.6±0.2, 8.5±0.2, 8.8±0.2, 14.3±0.2,  15.1±0.2, 16.2±0.2, 17.0±0.2,  17.7±0.2,  18.5±0.2, 18.8±0.2,20.0±0.2, 21.5±0.2, 23.6±0.2, 24.5±0.2, 27.4±0.2, 28.4±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 17 includes diffraction peaks at 15 or more 20 values selected from the group consisting of 8.2±0.2, 13.1±0.2, 14.8±0.2, 16.0±0.2, 17.6±0.2, 19.1±0.2, 19.8±0.2, 20.8±0.2, 22.4±0.2, 22.8±0.2, 23.8±0.2, 24.2±0.2, 24.5±0.2, 25.3±0.2, 26.5±0.2, and 29.3±0.2;the X-ray powder diffraction pattern of the crystal Form 18 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 6.7±0.2, 9.3±0.2, 10.5±0.2, 13.6±0.2, 15.5±0.2, 17.0±0.2, 18.6±0.2, 20.0±0.2, 20.5±0.2, 21.1±0.2,22.3±0.2, 23.5±0.2, 23.9±0.2, 24.7±0.2, 25.4±0.2, 26.1±0.2, 26.9±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 19 includes diffraction peaks at 16 or more 20 values selected from the group consisting of 7.3±0.2, 11.2±0.2, 14.6±0.2, 15.4±0.2, 17.2±0.2, 17.4±0.2, 18.0±0.2, 19.7±0.2, 20.6±0.2, 22.5±0.2, 23.1±0.2, 23.8±0.2, 24.8±0.2, 26.6±0.2, 27.5±0.2, 28.5±0.2, and 29.2±0.2;the X-ray powder diffraction pattern of the crystal Form 20 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 16 or 18) 20 values selected from the group consisting of 4.6±0.2, 9.1±0.2, 12.2±0.2, 13.7±0.2, 14.5±0.2, 17.7±0.2, 19.0±0.2, 19.7±0.2, 21.0±0.2, 21.6±0.2,22.8±0.2, 23.3±0.2, 24.1±0.2, 24.6±0.2, 26.2±0.2, 27.5±0.2, 28.8±0.2, and 32.2±0.2;the X-ray powder diffraction pattern of the crystal Form 21 includes diffraction peaks at ten or more (e.g., 12, 15, 18, 20 or 24) 20 values selected from the group consisting of 9.0±0.2, 11.2±0.2, 11.4±0.2, 12.1±0.2, 14.8±0.2, 15.9±0.2, 16.1±0.2, 17.7±0.2, 19.4±0.2, 19.7±0.2,20.2±0.2, 20.9±0.2, 21.6±0.2, 22.9±0.2, 23.8±0.2, 24.7±0.2, 26.1±0.2, 26.3±0.2, 27.6±0.2,28.3±0.2, 29.9±0.2, 31.5±0.2, and 33.4±0.2;the X-ray powder diffraction pattern of the crystal Form 22 includes diffraction peaks at ten or more (e.g., 12, 13, 15, 18 or 20) 20 values selected from the group consisting of 4.3±0.2,8.4±0.2, 12.4±0.2, 14.4±0.2, 16.8±0.2, 17.2±0.2, 18.3±0.2, 19.3±0.2, 20.5±0.2, 23.0±0.2,23.5±0.2, 23.8±0.2, 24.1±0.2, 24.7±0.2, 24.9±0.2, 25.8±0.2, 26.4±0.2, 33.8±0.2, 34.6±0.2, and 35.9±0.2;the X-ray powder diffraction pattern of the crystal Form 23 includes diffraction peaks at ten or more (e.g., 11, 12, 13, 14 or 15) 20 values selected from the group consisting of 8.0±0.2, 9.1±0.2, 12.0±0.2, 16.0±0.2, 17.8±0.2, 18.2±0.2, 18.5±0.2, 19.8±0.2, 21.5±0.2, 24.1±0.2,24.4±0.2, 24.8±0.2, 25.8±0.2, 27.8±0.2, and 30.4±0.2; and / orthe X-ray powder diffraction pattern of the crystal Form 24 includes diffraction peaks at ten or more (e.g., 12, 14, 15, 18 or 20) 20 values selected from the group consisting of 4.3±0.2, 8.6±0.2, 12.4±0.2, 13.9±0.2, 14.4±0.2, 16.2±0.2, 16.8±0.2, 18.0±0.2, 19.0±0.2, 19.3±0.2,19.6±0.2, 20.4±0.2, 20.8±0.2, 22.5±0.2, 23.4±0.2, 23.8±0.2, 24.6±0.2, 24.9±0.2, 25.3±0.2, and 27.9±0.2.

5. The salt crystal form according to claim 2, whereinthe crystal Figure 2;the crystalFigure 5;the crystalFigure 8;the crystal Figure 11;the crystal Figure 13;the crystal Figure 15;the crystal Figure 17;the crystal Figure 19;the crystal Figure 21;the crystal Figure 23;the crystal Figure 25;the crystal Figure 27;the crystal Figure 29;the crystal Figure 32;the crystal Figure 35;Form 1 has an X-ray powder diffraction pattern substantially as shown inForm 2 has an X-ray powder diffraction pattern substantially as shown inForm 3 has an X-ray powder diffraction pattern substantially as shown inForm 4 has an X-ray powder diffraction pattern substantially as shown inForm 5 has an X-ray powder diffraction pattern substantially as shown inForm 6 has an X-ray powder diffraction pattern substantially as shown inForm 7 has an X-ray powder diffraction pattern substantially as shown inForm 8 has an X-ray powder diffraction pattern substantially as shown inForm 9 has an X-ray powder diffraction pattern substantially as shown inForm 10 has an X-ray powder diffraction pattern substantially as shown inForm 11 has an X-ray powder diffraction pattern substantially as shown inFormFormFormForm12131415hashashashasananananX-rayX-rayX-rayX-raypowderpowderpowderpowderdiffractiondiffractiondiffractiondiffractionpattern substantiallypattern substantiallypattern substantiallypattern substantiallyasasasasshownshownshownshownininininthe crystal Form 16 has an Figure 38;the crystal Form 17 has an Figure 41;the crystal Form 18 has an Figure 43;the crystal Form 19 has an Figure 46;the crystal Form 20 has an Figure 48;the crystal Form 21 has an Figure 51;the crystal Form 22 has an Figure 54;the crystal Form 23 has an Figure 57; and / orthe crystal Form 24 has an Figure 60.X-ray powder diffractionX-ray powder diffractionX-ray powder diffractionX-ray powder diffractionX-ray powder diffractionX-ray powder diffractionX-ray powder diffractionX-ray powder diffractionX-ray powder diffractionpattern substantially as shown inpattern substantially as shown inpattern substantially as shown inpattern substantially as shown inpattern substantially as shown inpattern substantially as shown inpattern substantially as shown inpattern substantially as shown inpattern substantially as shown in6. The salt crystal form according to claim 2, wherein,in the crystal Form 1, the molar ratio of the compound of Formula I to oxalic acid is 0.8-1.5:0.8-1.5;in the crystal Form 2, the molar ratio of the compound of Formula I to maleic acid is 0.8-1.2:0.8-1.2;in the crystal Form 3, the molar ratio of the compound of Formula I to fumaric acid is 0.8-1.2:0.8-1.2;in the crystal Form 4, the molar ratio of the compound of Formula I to succinic acid is 0.8-1.2:0.8-1.2;in the crystal Form 5, the molar ratio of the compound of Formula I to D-tartaric acid is 0.8-1.2:0.8-1.2;in the crystal Form 6, the molar ratio of the compound of Formula I to L-tartaric acid is 0.8-1.2:0.8-1.2;in the crystal Form 7, the molar ratio of the compound of Formula I to D-malic acid is 0.8-1.2:0.8-1.2;in the crystal Form 8, the molar ratio of the compound of Formula I to L-malic acid is 0.8-1.2:0.8-1.2;in the crystal Form 9, the molar ratio of the compound of Formula I to L-glutamic acid is 0.8-1.2:0.8-1.2;in the crystal Form 10, the molar ratio of the compound of Formula I to citric acid is 0.8-1.2:0.8-1.2;in the crystal Form 11, the molar ratio of the compound of Formula I to benzoic acid is 0.8-1.2:0.8-1.2;in the crystal Form 12, the molar ratio of the compound of Formula I to salicylic acid is 0.8-1.2:0.8-1.2;in the crystal Form 13, the molar ratio of the compound of Formula I to methanesulfonic acid is 1:0.8-20;in the crystal Form 14, the molar ratio of the compound of Formula I to ethanesulfonic acid is 1:0.8-20;in the crystal Form 15, the molar ratio of the compound of Formula I to benzenesulfonic acid is 1:0.8-5;in the crystal Form 16, the molar ratio of the compound of Formula I to p-toluenesulfonic acid is 1:0.8-2;in the crystal Form 17, the molar ratio of the compound of Formula I to acetic acid is 1:0.8-2;in the crystal Form 18, the molar ratio of the compound of Formula I to trifluoroacetic acid is 1:0.8-20;in the crystal Form 19, the molar ratio of the compound of Formula I to propionic acid is 1:0.8-30;in the crystal Form 20, the molar ratio of the compound of Formula I to hydrochloric acid is 1:0.8-40;in the crystal Form 21, the molar ratio of the compound of Formula I to hydrobromic acid is 1:0.8-5;in the crystal Form 22, the molar ratio of the compound of Formula I to sulfuric acid is 1:0.8-20;in the crystal Form 23, the molar ratio of the compound of Formula I to phosphoric acid is 1:0.8-20; and / orin the crystal Form 24, the molar ratio of the compound of Formula I to nitric acid is 1:0.8-20.

7. A method for preparing the salt crystal form of the compound of Formula I according to the first aspect of the present invention, the method comprises steps of:mixing the compound of Formula I with a solvent, then adding a corresponding acid, and further mixing for crystallization or evaporation to obtain the salt crystal form.

8. The method according to claim 7, wherein the solvent is selected from the group consisting of methanol, dichloromethane, acetonitrile, ethyl acetate, acetone, and the combinations thereof.

9. A pharmaceutical composition, comprising the salt crystal form of the compound of Formula I according to claim 1, and a pharmaceutically acceptable carrier.

10. Use of the salt crystal form of the compound of Formula I according to claim 1 for preparing a pharmaceutical composition for preventing and / or treating cancer.

Images